

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 10-Q

X  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended September 28, 2003**

OR

TRANSITION REPORT PURSUANT TO SECTION 13  
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

COMMISSION FILE NUMBER 1-3619

----

**PFIZER INC.**

(Exact name of registrant as specified in its charter)

DELAWARE  
(State of Incorporation)

13-5315170  
(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017  
(212) 573-2323  
(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES  X  NO

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES  X  NO

At November 10, 2003, 7,631,522,869 shares of the issuer's common stock were outstanding (voting).

**FORM 10-Q**  
**For the Quarter Ended**  
**September 28, 2003**  
**Table of Contents**

<b>PART I. FINANCIAL INFORMATION</b>	<b>Page</b>
Item 1.	
Financial Statements:	
Condensed Consolidated Statement of Income for the three months and nine months ended September 28, 2003 and September 29, 2002	3
Condensed Consolidated Balance Sheet at September 28, 2003 and December 31, 2002	4
Condensed Consolidated Statement of Cash Flows for the nine months ended September 28, 2003 and September 29, 2002	5
Notes to Condensed Consolidated Financial Statements	6
Independent Accountants' Review Report	23
Item 2.	
Management's Discussion and Analysis of Financial Condition and Results of Operations	24
Item 4.	
Disclosure Controls and Procedures	48
<b>PART II. OTHER INFORMATION</b>	
Item 1.	
Legal Proceedings	49
Item 6.	
Exhibits and Reports on Form 8-K	51
Signature	52
Certifications	55

# **PART I. FINANCIAL INFORMATION**

## Item 1. Financial Statements

### **PFIZER INC. AND SUBSIDIARY COMPANIES** **CONDENSED CONSOLIDATED STATEMENT OF INCOME** **(UNAUDITED)**

	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
(millions of dollars, except per common share data)				
Revenues .....	\$ 12,504	\$ 7,996	\$ 31,022	\$ 23,039
Costs and expenses:				
Cost of sales .....	3,366	1,026	6,459	2,867
Selling, informational and administrative expenses .....	4,043	2,657	10,560	7,864
Research and development expenses .....	1,879	1,245	4,813	3,665
Merger-related in-process research and development charge.....	(87)	--	5,043	--
Merger-related costs .....	303	114	680	387
Other (income)/deductions-net .....	506	54	1,155	(77)
Income from continuing operations before provision for taxes on income, minority interests and cumulative effect of change in accounting principles .....	2,494	2,900	2,312	8,333
Provision for taxes on income .....	253	630	1,286	1,859
Minority interests .....	2	1	1	1
Income from continuing operations before cumulative effect of change in accounting principles.....	2,239	2,269	1,025	6,473
Discontinued operations:				
Income/(loss) from operations of discontinued businesses/product lines-net of tax.....	(4)	81	28	207
Gains on sales of discontinued businesses/product lines-net of tax.....	--	--	2,285	--
Discontinued operations-net of tax .....	(4)	81	2,313	207
Income before cumulative effect of change in accounting principles .....	2,235	2,350	3,338	6,680
Cumulative effect of change in accounting principles-net of tax .....	--	--	(30)	(410)
Net income .....	\$ 2,235	\$ 2,350	\$ 3,308	\$ 6,270
Earnings per common share - Basic:				
Income from continuing operations before cumulative effect of change in accounting principles .....	\$ .29	\$ .38	\$ .14	\$ 1.06
Discontinued operations:				
Income/(loss) from operations of discontinued businesses/product lines-net of tax...	--	.01	--	.03
Gains on sales of discontinued businesses/product lines-net of tax.....	--	--	.33	--
Discontinued operations-net of tax .....	--	.01	.33	.03
Income before cumulative effect of change in accounting principles .....	.29	.39	.47	1.09
Cumulative effect of change in accounting principles-net of tax .....	--	--	--	(.07)
Net income .....	\$ .29	\$ .39	\$ .47	\$ 1.02
Earnings per common share - Diluted:				
Income from continuing operations before cumulative effect of change in accounting principles .....	\$ .29	\$ .37	\$ .14	\$ 1.04
Discontinued operations:				
Income/(loss) from operations of discontinued businesses/product lines-net of tax...	--	.01	--	.03
Gains on sales of discontinued businesses/product lines-net of tax.....	--	--	.32	--
Discontinued operations-net of tax .....	--	.01	.32	.03
Income before cumulative effect of change in accounting principles .....	.29	.38	.46	1.07
Cumulative effect of change in accounting principles-net of tax .....	--	--	--	(.07)
Net income .....	\$ .29	\$ .38	\$ .46	\$ 1.00
Weighted average shares used to calculate earnings per common share:				
Basic.....	7,710.7	6,126.3	7,088.5	6,172.3
Diluted.....	7,791.2	6,202.2	7,160.7	6,262.2
Cash dividends paid per common share	\$ .15	\$ .13	\$ .45	\$ .39

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES  
CONDENSED CONSOLIDATED BALANCE SHEET  
(UNAUDITED)

(in millions)	Sept. 28, 2003*	Dec. 31, 2002**
<u>ASSETS</u>		
Current Assets		
Cash and cash equivalents.....	\$ 1,610	\$ 1,878
Short-term investments .....	12,807	10,673
Accounts receivable, less allowance for doubtful accounts: \$190 and \$122 .....	8,626	5,785
Short-term loans .....	340	399
Inventories		
Finished goods .....	2,035	1,133
Work in process .....	3,318	1,142
Raw materials and supplies.....	1,348	403
Total inventories .....	<u>6,701</u>	<u>2,678</u>
Prepaid expenses and taxes .....	2,983	1,797
Assets of discontinued businesses held for sale .....	--	1,571
Total current assets .....	<u>33,067</u>	<u>24,781</u>
Long-term loans and investments .....	5,962	5,161
Property, plant and equipment, less accumulated depreciation: \$6,377 and \$5,431 .....	17,961	10,712
Goodwill .....	22,972	1,200
Identifiable intangible assets, net .....	34,179	921
Other assets, deferred taxes and deferred charges.....	5,917	3,581
Total assets.....	<u>\$ 120,058</u>	<u>\$ 46,356</u>
<u>LIABILITIES AND SHAREHOLDERS' EQUITY</u>		
Current Liabilities		
Short-term borrowings, including current portion of long-term debt: \$115 and \$256.....	\$ 9,396	\$ 8,669
Accounts payable .....	1,998	1,620
Income taxes payable .....	3,678	2,231
Accrued compensation and related items .....	1,539	1,084
Other current liabilities .....	5,049	4,374
Liabilities of discontinued businesses held for sale .....	--	577
Total current liabilities .....	<u>21,660</u>	<u>18,555</u>
Long-term debt .....	6,439	3,140
Pension benefit obligations .....	2,634	910
Postretirement benefit obligations other than pension plans .....	1,417	623
Deferred taxes on income .....	14,880	364
Other noncurrent liabilities .....	4,497	2,814
Total liabilities .....	<u>51,527</u>	<u>26,406</u>
Shareholders' Equity		
Preferred stock .....	229	--
Common stock .....	434	341
Additional paid-in capital.....	65,918	9,368
Retained earnings.....	31,191	30,243
Accumulated other comprehensive expense .....	(1,434)	(1,875)
Employee benefit trust .....	(1,626)	(1,786)
Treasury stock, at cost.....	<u>(26,181)</u>	<u>(16,341)</u>
Total shareholders' equity .....	<u>68,531</u>	<u>19,950</u>
Total liabilities and shareholders' equity.....	<u>\$ 120,058</u>	<u>\$ 46,356</u>

\* Unaudited.

\*\* Condensed from audited financial statements.

See accompanying Notes to Condensed Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES  
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS  
(UNAUDITED)

(in millions)	Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002
<b>Operating Activities:</b>		
Net income .....	\$ 3,308	\$ 6,270
Adjustments to reconcile net income to net cash provided by continuing operating activities:		
Cumulative effect of change in accounting principles .....	30	410
Income from operations of discontinued businesses .....	(28)	(207)
Depreciation and amortization .....	2,327	736
Merger-related in-process research and development charge .....	5,043	--
Charge for fair value mark-up of acquired inventory .....	1,712	--
Charges to write-down equity investments .....	8	28
Gains on sales of discontinued businesses and product lines, net of tax .....	(2,285)	--
Gains on sales of products .....	(87)	(20)
Other .....	(311)	(17)
Changes in assets and liabilities (net of business acquired) .....	(2,388)	(939)
Net cash provided by continuing operating activities .....	7,329	6,261
<b>Investing Activities:</b>		
Purchases of property, plant and equipment .....	(1,862)	(1,172)
Purchases of short-term investments .....	(10,455)	(12,133)
Proceeds from redemptions of short-term investments .....	10,029	9,124
Purchases of long-term investments .....	(1,240)	(2,533)
Proceeds from redemptions of long-term investments .....	351	2,907
Purchases of other assets .....	(425)	(101)
Proceeds from sales of other assets .....	226	180
Proceeds from the sales of businesses and product lines .....	5,600	6
Cash and cash equivalents acquired through acquisition of Pharmacia .....	1,789	--
Other investment activities .....	(74)	20
Net cash provided by/(used in) investing activities .....	3,939	(3,702)
<b>Financing Activities:</b>		
Increase in short-term borrowings-net .....	814	4,657
Principal payments on short-term borrowings-net .....	(280)	(442)
Proceeds from issuances of long-term debt .....	600	600
Principal payments on long-term debt .....	(436)	(212)
Proceeds from common stock issuances .....	73	53
Purchases of common stock .....	(9,873)	(4,726)
Cash dividends paid .....	(3,276)	(2,382)
Stock option transactions and other .....	854	496
Net cash used in financing activities .....	(11,524)	(1,956)
Net cash provided by discontinued operations .....	14	139
Effect of exchange-rate changes on cash and cash equivalents .....	(26)	(4)
Net increase/(decrease) in cash and cash equivalents .....	(268)	738
Cash and cash equivalents at beginning of period .....	1,878	1,036
Cash and cash equivalents at end of period .....	\$ 1,610	\$ 1,774
<b>Supplemental Cash Flow Information:</b>		
Cash paid during the period for:		
Income taxes .....	\$ 2,108	\$ 1,089
Interest .....	235	208
Non-cash transactions:		
Issuance of common stock, preferred stock and stock options related to acquisition of Pharmacia, net of transaction costs .....	\$ 55,872	\$ --

See accompanying Notes to Condensed Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

Note 1: Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month and nine-month periods ended August 24, 2003 and August 25, 2002. We made certain reclassifications to the 2002 condensed consolidated financial statements to conform to the 2003 presentation.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

On April 16, 2003, we completed our acquisition of Pharmacia Corporation (Pharmacia) in a stock for stock transaction accounted for under the purchase method of accounting - see note 2, "Pharmacia Acquisition". Commencing with the date of acquisition, April 16, 2003, the Pharmacia assets acquired and liabilities assumed, as well as the results of Pharmacia's operations are included in our condensed consolidated financial statements. About 4 1/2 months of results of operations of Pharmacia's international operations and about 5 1/2 months of results of operations of Pharmacia's U.S. operations are included in our condensed consolidated financial statements for the nine-month period ended September 28, 2003.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative as those for the full year.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with:

- consolidated financial statements and accompanying notes included in Pfizer's Annual Report on Form 10-K for the year ended December 31, 2002;
- consolidated financial statements and accompanying notes included in Pharmacia's Annual Report on Form 10-K for the year ended December 31, 2002; and
- unaudited pro forma condensed combined financial statements and accompanying notes as of and for the year ended December 31, 2002 included in Pfizer's Current Report on Form 8-K/A dated June 30, 2003.

In accordance with Statement of Financial Accounting Standards (SFAS) No. 123, *Accounting for Stock-Based Compensation*, we elected to account for our stock-based compensation under Accounting Principles Board Opinion (APB) No. 25, *Accounting for Stock Issued to Employees*. The exercise price of stock options granted equals the market price on the date of grant. There is no recorded expense related to grants of stock options.

The weighted-average fair value per stock option granted was \$8.46 for the three months ended September 28, 2003, \$8.78 for the three months ended September 29, 2002, \$7.35 for the nine months ended September 28, 2003 and \$12.58 for the nine months ended September 29, 2002. We estimated the fair values, as required under GAAP, using the Black-Scholes option-pricing model, modified for dividends and using the assumptions below. The Black-Scholes model is a trading option-pricing model that neither considers the non-traded nature of employee stock options, nor the restrictions on trading, the lack of transferability or the ability of employees to forfeit the options prior to expiry. If the model adequately permitted considerations of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different.

	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
Expected dividend yield	2.81%	2.71%	3.15%	1.90%
Risk-free interest rate	3.27%	3.86%	2.75%	4.35%
Expected stock price volatility	33.08%	32.93%	33.05%	32.41%
Expected term until exercise (years)	5.46	5.50	5.58	5.30

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

The following table summarizes our results for the three months and nine months ended September 28, 2003 and September 29, 2002 as if we had recorded compensation expense for the options grants:

(millions of dollars, except per common share data)	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
Net income available to common shareholders used in the calculation of basic earnings per common share:				
As reported under GAAP*	\$ 2,234	\$ 2,350	\$ 3,306	\$ 6,270
Compensation expense	(143)	(160)	(394)	(380)
Pro forma	<u>\$ 2,091</u>	<u>\$ 2,190</u>	<u>\$ 2,912</u>	<u>\$ 5,890</u>
Basic earnings per common share:				
As reported under GAAP*	\$ .29	\$ .39	\$ .47	\$ 1.02
Compensation expense	(.02)	(.03)	(.06)	(.07)
Pro forma	<u>\$ .27</u>	<u>\$ .36</u>	<u>\$ .41</u>	<u>\$ .95</u>
Net income available to common shareholders used in the calculation of diluted earnings per common share:				
As reported under GAAP*	\$ 2,234	\$ 2,350	\$ 3,306	\$ 6,270
Compensation expense	(143)	(160)	(394)	(380)
Pro forma	<u>\$ 2,091</u>	<u>\$ 2,190</u>	<u>\$ 2,912</u>	<u>\$ 5,890</u>
Diluted earnings per common share:				
As reported under GAAP*	\$ .29	\$ .38	\$ .46	\$ 1.00
Compensation expense	(.02)	(.03)	(.05)	(.06)
Pro forma	<u>\$ .27</u>	<u>\$ .35</u>	<u>\$ .41</u>	<u>\$ .94</u>

\* Includes stock based compensation expense, net of related tax effects, of \$28 million for the nine months ended September 28, 2003 (\$1 million income for the three months ended September 28, 2003) and \$10 million for the nine months ended September 29, 2002 (\$6 million income for the three months ended September 29, 2002).

Net income available to common shareholders used in the calculation of basic earnings per common share represents net income reduced by preferred stock dividends-net of tax. Net income available to common shareholders used in the calculation of diluted earnings per common share represents net income reduced by the incremental contribution to the Employee Stock Ownership Plan (ESOP), acquired as part of the Pharmacia acquisition.

#### Note 2: Pharmacia Acquisition

On April 16, 2003, Pfizer acquired Pharmacia for a purchase price of approximately \$56 billion, which includes Pfizer common stock valued at \$54.2 billion, options on Pfizer common stock valued at \$1.1 billion, Pfizer convertible perpetual preferred stock valued at \$.5 billion, and vested share awards valued at \$.1 billion, as well as transaction costs of \$90 million.

The fair value of Pfizer common stock was derived using an average market price per share of Pfizer common stock of \$29.81, which was based on Pfizer's average stock price for the period two days before through two days after the terms of the acquisition were agreed to and announced on July 15, 2002.

Under the terms of the merger agreement, each outstanding share of Pharmacia common stock was exchanged for 1.4 shares of Pfizer common stock in a tax-free transaction. Each share of Pharmacia Series C convertible perpetual preferred stock was exchanged for a newly created class of Pfizer Series A convertible perpetual preferred stock with rights substantially similar to the rights of the Pharmacia Series C convertible perpetual preferred stock.

The acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed from Pharmacia are recorded at the date of acquisition, at their respective fair values. The consolidated financial statements and reported results of operations of Pfizer issued after completion of the acquisition

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

will reflect these values, but will not be restated retroactively to reflect the historical financial position or results of operations of Pharmacia.

The following is an estimate of the purchase price for Pharmacia, as of April 16, 2003:

**Common Stock**

Number of shares of Pharmacia common stock outstanding as of April 16, 2003 (in thousands)	1,298,157	
Exchange ratio	<u>1.4</u>	
	1,817,420	
Multiplied by Pfizer's average stock price for the period two days before through two days after the July 15, 2002 announcement of the merger agreement	\$ <u>29.81</u>	\$ 54,177 million

**Preferred Stock**

Number of shares of Pharmacia Series B perpetual preferred stock to be exchanged for substantially similar Pharmacia Series C perpetual preferred stock, outstanding and convertible into common stock as of April 16, 2003	6,028.931	
Conversion feature	<u>1,839.19</u>	
Number of shares of Pharmacia common stock issuable upon conversion (in thousands)	11,088,350	
Exchange ratio	<u>1.4</u>	
	15,523,690	
Multiplied by Pfizer's average stock price for the period two days before through two days after the July 15, 2002 announcement of the merger agreement	\$ <u>29.81</u>	463 million

**Stock Options**

Estimated fair value of 180,068 Pfizer stock options (in thousands) issued as of April 16, 2003 in exchange for 128,906 Pharmacia outstanding stock options (in thousands), calculated using the Black-Scholes option pricing model, modified for dividends, with model assumptions estimated as of April 16, 2003 and a Pfizer stock price of \$29.81, which represented the average stock price for the period two days before through two days after the July 15, 2002 announcement of the merger agreement	1,102 million
--	---------------

**Vested Share Award Programs**

Share awards became fully vested in connection with the acquisition. The fair value of unissued shares of fully vested awards is based on the same exchange ratio as the common stock and a Pfizer stock price of \$29.81. Awards can be settled in cash or shares, at the election of the program participant	130 million
--	-------------

<b>Other transaction costs</b>	<u>90 million</u>
--------------------------------	-------------------

<b>Total estimated purchase price</b>	<u>\$ 55,962 million</u>
---------------------------------------	--------------------------



PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

The above purchase price has been preliminarily allocated based on an estimate of the fair value of assets acquired and liabilities assumed. The final valuation of net assets is expected to be completed as soon as possible, but no later than one year from the acquisition date in accordance with GAAP. To the extent that our estimates need to be adjusted, we will do so.

(in millions)	
Estimated book value of net assets acquired	\$ 8,684
Adjusted for write-off of existing goodwill and other intangible assets	<u>1,448</u>
Adjusted estimated book value of net assets acquired	<u>7,236</u>
Remaining allocation:	
Increase inventory to fair value <sup>(a)</sup>	3,324
Increase long-term investments to fair value <sup>(b)</sup>	40
Increase property, plant and equipment to fair value <sup>(c)</sup>	775
Record in-process research and development charge <sup>(d)</sup>	5,043
Record identifiable intangible assets <sup>(e)</sup>	34,540
Increase long-term debt to fair value	(370)
Increase benefit plan liabilities to fair value <sup>(f)</sup>	(1,349)
Increase other noncurrent liabilities to fair value <sup>(g)</sup>	(307)
Restructuring costs incurred through September 28, 2003 <sup>(h)</sup>	(1,319)
Deferred taxes <sup>(i)</sup>	(13,388)
Goodwill <sup>(j)</sup>	<u>21,737</u>
Estimated purchase price	<u>\$ 55,962</u>

<sup>(a)</sup> Components of the increase to fair value for acquired inventory is as follows:

(in millions)	
Finished goods	\$ 362
Work in process	2,693
Reversal of LIFO Reserve	<u>269</u>
Total	<u>\$ 3,324</u>

We have conformed Pharmacia inventory valuation methods to Pfizer's methodology, and as such, will no longer use the LIFO method of inventory valuation for these inventories.

<sup>(b)</sup> Primarily related to one publicly-traded, equity-method investment adjusted to fair value. The basis for the valuation was the quoted market price from the Stockholm Exchange.

<sup>(c)</sup> Components of the increase to fair value for acquired property, plant and equipment is as follows:

(in millions)	
Land	\$ (27)
Buildings	789
Machinery and equipment	<u>13</u>
Total	<u>\$ 775</u>

<sup>(d)</sup> As required by Financial Accounting Standards Board Interpretation No. 4, *Applicability of FASB Statement No. 2 to Business Combinations Accounted for by the Purchase Method* (FIN 4), we recorded a charge of \$5,043 million for the preliminary estimate of the portion of the purchase price allocated to acquired in-process research and development.

A project-by-project valuation using the guidance in SFAS No. 141, *Business Combinations* and the AICPA Practice Aid *Assets Acquired in a Business Combination to be Used in Research and Development Activities: A Focus on Software, Electronic Devices and Pharmaceutical Industries* (Practice Aid) is being performed by independent valuation specialists to determine the fair value of research and development projects of Pharmacia which were in-process, but not yet completed (collectively, In-Process Research and Development or IPR&D).

The fair value is determined using the income approach on a project-by-project basis. This method starts with a forecast of the expected future net cash flows. These cash flows are then adjusted to present value by applying an appropriate discount

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

rate that reflects the project's stage of completion and other risk factors. (These other risk factors can include the nature of the product, the scientific data associated with the technology, the current patent situation and market competition.)

The forecast of future cash flows required the following assumptions to be made:

- Revenue that is reasonably likely to result from specific in-process research and development projects, if they are successful, including the estimated number of units to be sold, estimated selling prices, estimated market penetration and estimated market share and year-over-year growth rates over the product life cycles.
- Cost of sales related to the potential products using historical data, industry data or other sources of market data.
- Sales and marketing expense using historical data, industry data or other sources of market data.
- General and administrative expenses.
- Research and development (R&D) expenses.

In addition, we considered:

- The project's stage of completion
- The costs incurred to date
- The projected costs to complete
- The contribution, if any, of developed technology
- The projected launch date of the potential product
- The estimated life of the potential product.

To the extent that the IPR&D project is expected to utilize developed technology, the value of the in-process research and development project has been reduced to reflect this contribution. Developed technology represents the technical processes, intellectual property, and institutional understanding that were acquired from Pharmacia with respect to products, compounds and/or processes that have been completed and that may aid in the development of future products or processes.

<sup>(e)</sup> Adjustment to record acquired identifiable intangible assets at fair value. A preliminary list of the acquired identifiable intangible assets is as follows:

- a. Developed technology
- b. Trademark/Brand names
- c. Customer lists/relationships
- d. Distribution agreements
- e. Supply agreements

The acquired identifiable intangible assets are attributable to the following categories:

	(in millions)	Useful Lives (years)
Developed technology rights	\$24,871	3 - 20
Brands (finite-lived assets)	100	40
Brands (indefinite-lived assets)	8,917	
Other (finite-lived assets)	143	2 - 20
Other (indefinite-lived assets)	509	
Total	<u>\$34,540</u>	

Acquired identifiable intangible assets have been substantially allocated to the pharmaceutical segment (\$32.3 billion).

Developed technology rights represent the value associated with developed technology to which Pfizer has all associated rights. These rights can include the right to develop, use, market, sell and/or offer for sale the technical processes, intellectual property and institutional understanding (including the way in which compounds react in body, an understanding of the mechanisms of action which allows the compound to work and the knowledge related to the associated clinical and marketing studies performed for these compounds) that were acquired from Pharmacia with respect to products, compounds and/or processes that have been completed. The valuation of these developed technology rights is derived from multiple cash flow streams, some of which are more certain than others. For example, the valuation of Pharmacia's second-generation COX-2 inhibitor, *valdecoxib*, includes the cash flows associated with the sale of Bextra, the product line approved by regulators for the treatment of osteo and rheumatoid arthritis, as well as the value associated with using the developed technology

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

(*valdecoxib*) in future IPR&D projects. In this situation, the cash flows of the approved indications are more likely to be achieved than the potential cash flows associated with the R&D projects for the currently unapproved indications. The unequal probability of realizing these cash flow streams reflects the uncertainty associated with the future benefits of individual R&D projects, even those that leverage the benefits of developed technology. Of the value allocated to developed technology rights, approximately 95% is derived from regulatory-approved uses and indications.

Brands with indefinite-life treatment represent the value associated with tradenames, as the products themselves no longer receive patent protection.

The fair value of all of these intangible assets is determined using an income approach on a project-by-project basis. This method starts with a forecast of all of the expected future net cash flows associated with the developed technology (both approved and unapproved uses), the brands and the other intangible assets. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

The forecast of future cash flows requires the following assumptions to be made:

- Revenue that is reasonably likely to result from the approved and unapproved uses, if they are successful, including the estimated number of units to be sold, estimated selling prices, estimated market penetration and estimated market share and year-over-year growth rates over the product life cycles,
- Cost of sales related to the potential products using historical data, industry data or other sources of market data,
- Sales and marketing expense using historical data, industry data or other sources of market data,
- General and administrative expenses,
- Research and development (R&D) expenses, and
- The estimated life of the potential product.

The valuations are based on the information that is currently available and the expectations and assumptions that have been deemed reasonable by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will occur as projected. For these reasons, among others, the actual results may vary from the projected results.

At least annually, we will evaluate all of these intangible assets for impairment. For developed technology rights, an element of the impairment review process will include an evaluation of the status of the various R&D programs that were a part of the fair valuation process. Given the general uncertainty of success that is associated with R&D projects in the pharmaceutical industry, the realization of these cash flow streams (those associated with unapproved indication) are not assured.

<sup>(f)</sup> Adjust benefit plan liabilities to fair value. Adjustment is included in *Postretirement benefit obligation other than pension plans* - \$292 million and *Pension benefit obligations* - \$1,057 million for pension obligations.

<sup>(g)</sup> Includes accruals for legal and environmental matters that we intend to resolve in a manner different from the manner Pharmacia had planned. Also, includes accruals for unfavorable leases and award programs which became fully vested in connection with the acquisition as well as the reversal of Pharmacia deferred income that no longer represents a performance obligation to third parties.

<sup>(h)</sup> Included in *Other current liabilities* are restructuring costs that impacted goodwill. These exit costs are associated with Pharmacia employees, assets or activities and were recorded as a liability in conjunction with recording the initial purchase of Pharmacia.

<sup>(i)</sup> Reflects the estimated tax effects of the acquisition, including a provision for taxes on unremitted earnings of international Pharmacia subsidiaries that are not expected to be permanently reinvested overseas.

<sup>(j)</sup> In accordance with the requirements of SFAS No. 142, *Goodwill and Other Intangible Assets*, the goodwill and the acquired indefinite-lived intangibles associated with the merger will not be amortized. Goodwill resulting from this acquisition has been preliminarily allocated to the pharmaceutical segment (\$20.0 billion) and the consumer healthcare segment (\$1.7 billion).

The following unaudited pro forma financial information presents the combined results of operations of Pfizer and Pharmacia as if the acquisition had occurred as of the beginning of the periods presented. The unaudited pro forma financial information is not necessarily indicative of what our consolidated results of operations actually would have been had we completed the acquisition at the dates indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined company.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
(in millions, except per common share amounts)	(unaudited)		(unaudited)	
Revenues	\$ 12,504	\$ 11,209	\$ 34,728	\$ 32,331
Income from continuing operations before cumulative effect of change in accounting principles	3,067	2,370	7,044	6,833
Net income	3,063	1,430	9,248	4,806
Per share amounts:				
Income from continuing operations before cumulative effect of change in accounting principles per common share- <b>basic</b>	.40	.30	.90	.86
Net income per common share- <b>basic</b>	.40	.18	1.18	.60
Income from continuing operations before cumulative effect of change in accounting principles per common share- <b>diluted</b>	.39	.30	.89	.84
Net income per common share- <b>diluted</b>	.39	.18	1.17	.59

The unaudited pro forma financial information above reflects the following:

- a. The elimination of balances and transactions between Pfizer and Pharmacia, which upon completion of the merger would be considered intercompany balances and transactions. The majority of these transactions occurred under the Celebrex and Bextra marketing agreements. The entries include:
  - the elimination of certain sales, alliance revenue and certain co-promotion expenses; and
  - the elimination of the impact of milestone payments made by Pfizer to Pharmacia.
- b. The elimination of historical amortization expense recorded by legacy Pharmacia related to definite-lived intangible assets.
- c. A decrease in interest expense of \$9 million and \$27 million in the third quarter and first nine months of 2003 and \$9 million and \$29 million in the third quarter and first nine months of 2002 related to the estimated fair value adjustment of long-term debt from the purchase price allocation.
- d. Additional amortization expense related to the estimated fair value of identifiable intangible assets from the purchase price allocation, which are being amortized over their estimated useful lives over a range of 2 to 40 years, of approximately \$655 million and \$2,069 million in the third quarter and first nine months of 2003 and \$703 million and \$2,108 million in the third quarter and first nine months of 2002.
- e. Additional depreciation expense related to the estimated fair value step-up of the property, plant and equipment from the purchase price allocation, which is being depreciated over its estimated useful life of approximately \$49 million and \$97 million in the third quarter and first nine months of 2003 and \$17 million and \$51 million in the third quarter and first nine months of 2002.

The unaudited pro forma financial information above excludes the following material, non-recurring charges in the three and nine month periods ended September 28, 2003:

- purchase accounting adjustments related to purchased IPR&D a credit of \$87 million and charges of \$5,043 million and charges of \$1,304 million and \$1,712 million reported in *Cost of Sales* for the workdown of purchased inventory that was written up to fair value.

Note 3: Adoption of New Accounting Standards

*Accounting for Asset Retirement Obligations*

On January 1, 2003, we adopted the provisions of SFAS No. 143, *Accounting for Asset Retirement Obligations*. SFAS No. 143 addresses financial accounting requirements for retirement obligations associated with tangible long-lived assets. As a result of adopting SFAS No. 143, we recorded a non-cash pre-tax charge of \$47 million (\$30 million net of tax) in the first quarter of 2003 for the change in accounting for costs associated with the eventual retirement of certain manufacturing and

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

research facilities. This charge is reported as a one-time cumulative effect of a change in accounting principle as of the beginning of 2003. Our asset retirement obligations primarily relate to remediation and land restoration requirements.

*Accounting for Costs Associated with Exit or Disposal Activities*

On January 1, 2003, we adopted the provisions of SFAS No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*. SFAS No. 146 applies to costs associated with an exit activity that is not related to an entity newly acquired in a business combination. SFAS No. 146 amends existing accounting rules for these costs by requiring that a liability be recorded at fair value when incurred. The liability is subject to adjustment for the passage of time, timing of payments and changes in the estimated payments. SFAS No. 146 also provides specific guidance for lease termination costs and one-time employee termination benefits when incurred as part of an exit or disposal activity. SFAS No. 146 changes the measurement and timing of costs associated with exit and disposal activities initiated after December 31, 2002.

**Note 4: Goodwill and Other Intangible Assets**

The changes in the carrying amount of goodwill for the nine months ended September 28, 2003, by segment, follow:

(in millions)	Pharmaceutical	Consumer Healthcare	Other	Total
Balance, December 31, 2002	\$ 362	\$ 829	\$ 9	\$ 1,200
Goodwill - Pharmacia acquisition (preliminary estimate)	20,063	1,674	--	21,737
Other changes during the period*	30	5	--	35
Balance, September 28, 2003	<u>\$ 20,455</u>	<u>\$ 2,508</u>	<u>\$ 9</u>	<u>\$ 22,972</u>

\*Primarily reflects the impact of foreign exchange.

(in millions)	Gross Carrying Amount		Accumulated Amortization	
	Sept 28, 2003	Dec. 31, 2002	Sept. 28, 2003	Dec. 31, 2002
<b>Amortized intangible assets:</b>				
Developed technology rights	\$ 24,871	\$ --	\$ (1,241)	\$ --
Trademarks	139	133	(75)	(72)
License agreements	50	42	(11)	(25)
Patents	35	33	(29)	(24)
Product rights*	549	526	(108)	(72)
Noncompete agreements	49	48	(43)	(39)
Customer contracts	143	--	(15)	--
Other	187	78	(41)	(31)
Total amortized intangible assets	<u>26,023</u>	<u>860</u>	<u>(1,563)</u>	<u>(263)</u>
<b>Unamortized identifiable intangible assets:</b>				
Brands acquired as part of the Pharmacia acquisition	8,917	--	--	--
License agreements	480	--	--	--
Trademarks	235	240	--	--
Pension asset	34	60	--	--
Other	53	24	--	--
Total unamortized intangible assets	<u>9,719</u>	<u>324</u>	<u>--</u>	<u>--</u>
<b>Total identifiable intangible assets</b>	<u>\$ 35,742</u>	<u>\$ 1,184</u>	<u>\$ (1,563)</u>	<u>\$ (263)</u>

\* Includes a post-approval milestone payment that we made during the first quarter of 2003 under our alliance agreement for Celebrex. Such payment was made prior to the completion of our acquisition of Pharmacia.

Total amortization expense for finite-lived intangible assets was \$686 million for the three months ended September 28, 2003 and \$1,308 million for the nine months ended September 28, 2003. Amortization expense for finite-lived intangible assets is recorded in various expenses in the condensed consolidated statement of income, including *Cost of sales*, *Research and development expenses* and *Other (income)/deductions-net*.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

The annual amortization expense expected for the years 2003 through 2008 is as follows:

	(in millions)
2003	\$2,067
2004	\$2,884
2005	\$2,880
2006	\$2,747
2007	\$2,629
2008	\$2,225

Note 5: Financial Instruments

A. Long-Term Debt

In February 2003, we issued:

- \$300 million senior unsecured notes, due March 2009, which pay interest semi-annually, beginning on September 2, 2003, at a rate of 3.3%; and
- \$300 million senior unsecured notes, due March 2018, which pay interest semi-annually, beginning on September 1, 2003, at a rate of 4.65%.

The notes were issued under a \$5 billion debt shelf registration statement filed with the SEC in November 2002.

B. Derivative Financial Instruments and Hedging Activities

During the first nine months of 2003, we entered into the following incremental or new derivative and hedging activities:

*Foreign Exchange Risk*

These foreign exchange financial instruments serve to protect net income against the impact of the translation into U.S. dollars of certain foreign currency denominated transactions (in millions):

Financial Instrument	Hedge Type	Hedged or Offset Item	Notional Amount	Maturity Date
Forward contracts	--	Short-term foreign currency assets and liabilities	\$3,033	Through 2003
Forward contracts	Cash flow	Euro available-for-sale investments	1,950	Through 2003
Forward contracts	Cash flow	Australian dollar intercompany loan	281	Through 2003
Forward contracts	Cash flow	Swedish kroner intercompany deposit	209	Through 2003

*Interest Rate Risk*

The derivative financial instruments employed to manage interest rate risk follow (in millions):

Financial Instrument	Hedge Type	Hedged or Offset Item	Notional Amount	Maturity Date
Principal amortizing swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	\$660	2028
Swaps	Fair value	U.S. dollar fixed rate investment <sup>(1)</sup>	500	2008
Principal amortizing swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	461	2018
Swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	375	2005
Swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	300	2009
Swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	300	2018
Swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	200	2008
Principal amortizing swaps	Fair value	U.S. dollar fixed rate debt <sup>(1)</sup>	200	2027

<sup>(1)</sup> Serves to reduce exposure to long-term U.S. dollar interest rates by effectively converting fixed rates associated with long-term assets or debt obligations to floating rates.

There was no material ineffectiveness in any hedging relationship reported in earnings in the first nine months of 2003.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

Note 6: Merger-Related Costs

We incurred the following merger-related costs in connection with our merger with Warner-Lambert Company (Warner-Lambert) which was completed on June 19, 2000 and our acquisition of Pharmacia which was completed on April 16, 2003:

(in millions)	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
Integration costs - Warner-Lambert	\$ 2	\$ 99	\$ 23	\$ 276
Integration costs - Pharmacia	251	1	552	1
Restructuring charges - Warner-Lambert	(4)	14	(1)	110
Restructuring charges - Pharmacia	54	--	106	--
Total merger-related costs	<u>\$ 303</u>	<u>\$ 114</u>	<u>\$ 680</u>	<u>\$ 387</u>

Integration costs represent external, incremental costs directly related to our merger with Warner-Lambert and acquisition of Pharmacia, including expenditures for consulting and systems integration.

*Restructuring Charges - Warner-Lambert*

The components of the restructuring charges associated with the merger of the Warner-Lambert operations follow:

(in millions)	Provisions					Utilization Through Sept. 28, 2003	Reserve* Sept. 28, 2003
	Year 2000	Year 2001	Year 2002	Nine Months Ended Sept. 28, 2003	Total		
Employee termination costs	\$ 850	\$ 249	\$ 170	\$ (1)	\$ 1,268	\$ (1,260)	\$ 8
Property, plant and equipment	46	84	4	--	134	(134)	--
Other	21	30	13	--	64	(64)	--
	<u>\$ 917</u>	<u>\$ 363</u>	<u>\$ 187</u>	<u>\$ (1)</u>	<u>\$ 1,466</u>	<u>\$ (1,458)</u>	<u>\$ 8</u>

\*Included in *Other current liabilities*.

Through September 28, 2003, the charges for employee termination costs represent the approved reduction of our work force of our continuing businesses by 8,067 people, mainly in administrative functions for corporate, manufacturing, distribution, sales and research. We notified affected individuals and as of September 28, 2003, 7,697 employees were terminated. Employee termination costs include accrued severance benefits and costs associated with change-in-control provisions of certain Warner-Lambert employment contracts. Under the terms of Warner-Lambert employment contracts, certain terminated employees may elect to defer receipt of severance benefits. Severance benefits deferred for future payments were \$230 million at September 28, 2003 and \$218 million at December 31, 2002. The deferred severance benefits are considered utilized charges and are included in *Other noncurrent liabilities* in the condensed balance sheet.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

*Restructuring Charges - Pharmacia*

During the second and third quarters of 2003, in connection with the acquisition of Pharmacia, Pfizer management approved and initiated plans to restructure the operations of both legacy Pfizer and legacy Pharmacia to eliminate duplicative facilities and reduce costs.

We recorded \$106 million of restructuring costs associated primarily with exiting certain activities of legacy Pfizer, including severance, costs of vacating duplicative facilities and contract termination costs. These costs have been recorded as a charge to the results of operations through the nine months ended September 28, 2003 and are included in *Merger-related costs*. The components of the restructuring charges associated with the acquisition of Pharmacia which were expensed in 2003 follow:

	Provisions		Utilization Through Sept. 28, 2003	Reserve* Sept. 28, 2003
	Nine Months Ended Sept. 28, 2003	Total		
(in millions)				
Employee termination costs	\$ 76	\$ 76	\$ (44)	\$ 32
Asset impairments	15	15	(15)	--
Other	15	15	(4)	11
	<u>\$ 106</u>	<u>\$ 106</u>	<u>\$ (63)</u>	<u>\$ 43</u>

\*Included in *Other current liabilities*.

Through September 28, 2003, the charges for employee termination costs represent the approved reduction of the legacy Pfizer work force by 865 people, mainly in administrative functions for corporate, manufacturing, distribution, sales and research. We notified affected individuals and as of September 28, 2003, 706 employees were terminated. Asset impairments primarily include charges to write-down property, plant and equipment. Other primarily includes costs to exit certain activities of legacy Pfizer.

*Pharmacia Acquisition-Related Restructuring Costs Capitalized in 2003 as a Cost of the Acquisition*

We recorded \$1,319 million of similar restructuring costs associated primarily with exiting certain activities of legacy Pharmacia. These costs are accounted for under Emerging Issues Task Force (EITF) Issue No. 95-3, *Recognition of Liabilities in Connection with Purchase Business Combinations*, and were recognized as a liability assumed in the purchase business combination. Accordingly, these costs were included in the allocation of the cost to acquire Pharmacia and have been recorded as an increase to goodwill. In accordance with EITF 95-3, these restructuring costs also include costs associated with relocation. The restructuring liabilities are included in *Other current liabilities*. The components of the restructuring costs capitalized in 2003 as a cost of the acquisition of Pharmacia follow:

	Costs Incurred		Utilization Through Sept. 28, 2003	Reserve Sept. 28, 2003
	Nine Months Ended Sept. 28, 2003	Total		
(in millions)				
Employee termination costs	\$ 1,065	\$ 1,065	\$ (742)	\$ 323
Asset impairments	27	27	(27)	--
Relocation costs	96	96	(24)	72
Other	131	131	(11)	120
	<u>\$ 1,319</u>	<u>\$ 1,319</u>	<u>\$ (804)</u>	<u>\$ 515</u>

Through September 28, 2003, the employee termination costs represent the approved reduction of the legacy Pharmacia work force by 9,425 people, mainly in corporate, manufacturing, distribution, sales and research. We notified affected individuals and as of September 28, 2003, 8,271 employees were terminated. Employee termination costs include accrued severance benefits and costs associated with change in control provisions of certain Pharmacia employment contracts. Asset



PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

impairments primarily include charges to write-down property, plant and equipment. Other includes costs to exit certain activities of legacy Pharmacia.

Changes to the estimates of completing the currently approved restructuring plans or costs related to new restructuring initiatives will be recorded in results of operations for legacy Pfizer and will be recorded in goodwill for legacy Pharmacia for one year following the acquisition date of April 16, 2003.

Note 7: Comprehensive Income

	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
(in millions)				
Net income	\$ 2,235	\$ 2,350	\$ 3,308	\$ 6,270
Other comprehensive income/(expense):				
Holding gain/(loss) on investment securities arising during period-net of tax	(12)	28	(157)	(43)
Reclassification adjustment-net of tax	--	--	5	--
Net gain/(loss) on investment securities	(12)	28	(152)	(43)
Currency translation adjustment and hedges	(806)	250	593	114
Total other comprehensive income/(expense)	(818)	278	441	71
Total comprehensive income	\$ 1,417	\$ 2,628	\$ 3,749	\$ 6,341

The change in currency translation adjustment and hedges included in *Accumulated other comprehensive expense* for the first nine months of 2003 was:

(in millions)	2003
Opening balance	\$(1,438)
Translation adjustments and hedges	593
Ending balance	\$ (845)

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

Note 8: Earnings Per Common Share

Basic and diluted earnings per common share (EPS) were computed using the following common share data:

(in millions)	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
<b>EPS Numerator - Basic:</b>				
Income from continuing operations before cumulative effect of change in accounting principles	\$ 2,239	\$ 2,269	\$ 1,025	\$ 6,473
Less: Preferred stock dividends - net of tax	<u>1</u>	<u>--</u>	<u>2</u>	<u>--</u>
Income available to common shareholders from continuing operations before cumulative effect of change in accounting principles	<u>2,238</u>	<u>2,269</u>	<u>1,023</u>	<u>6,473</u>
Discontinued operations:				
Income/(loss) from operations of discontinued businesses/product lines-net of tax	(4)	81	28	207
Gains on sales of discontinued businesses/product lines-net of tax	<u>--</u>	<u>--</u>	<u>2,285</u>	<u>--</u>
Discontinued operations-net of tax	<u>(4)</u>	<u>81</u>	<u>2,313</u>	<u>207</u>
Income available to common shareholders before cumulative effect of change in accounting principles	2,234	2,350	3,336	6,680
Cumulative effect of change in accounting principles-net of tax	<u>--</u>	<u>--</u>	<u>(30)</u>	<u>(410)</u>
Net income available to common shareholders	<u>\$ 2,234</u>	<u>\$ 2,350</u>	<u>\$ 3,306</u>	<u>\$ 6,270</u>
<b>EPS Denominator - Basic:</b>				
Weighted average number of common shares outstanding	<u>7,710.7</u>	<u>6,126.3</u>	<u>7,088.5</u>	<u>6,172.3</u>
<b>EPS Numerator - Diluted:</b>				
Income from continuing operations before cumulative effect of change in accounting principles	\$ 2,239	\$ 2,269	\$ 1,025	\$ 6,473
Less: ESOP contribution - net of tax	<u>1</u>	<u>--</u>	<u>2</u>	<u>--</u>
Income available to common shareholders from continuing operations before cumulative effect of change in accounting principles	<u>2,238</u>	<u>2,269</u>	<u>1,023</u>	<u>6,473</u>
Discontinued operations:				
Income/(loss) from operations of discontinued businesses/product lines-net of tax	(4)	81	28	207
Gains on sales of discontinued businesses/product lines-net of tax	<u>--</u>	<u>--</u>	<u>2,285</u>	<u>--</u>
Discontinued operations-net of tax	<u>(4)</u>	<u>81</u>	<u>2,313</u>	<u>207</u>
Income available to common shareholders before cumulative effect of change in accounting principles	2,234	2,350	3,336	6,680
Cumulative effect of change in accounting principles-net of tax	<u>--</u>	<u>--</u>	<u>(30)</u>	<u>(410)</u>
Net income available to common shareholders	<u>\$ 2,234</u>	<u>\$ 2,350</u>	<u>\$ 3,306</u>	<u>\$ 6,270</u>
<b>EPS Denominator - Diluted:</b>				
Weighted average number of common shares outstanding	7,710.7	6,126.3	7,088.5	6,172.3
Common share equivalents--stock options, stock issuable under employee compensation plans and convertible preferred stock	<u>80.5</u>	<u>75.9</u>	<u>72.2</u>	<u>89.9</u>
Weighted average number of common shares outstanding and common share equivalents	<u>7,791.2</u>	<u>6,202.2</u>	<u>7,160.7</u>	<u>6,262.2</u>

Stock options and stock issuable under employee compensation plans representing equivalents of 317 million and 336 million shares of common stock during the three months and nine months ended September 28, 2003 and 297 million and 204 million shares of common stock during the three months and nine months ended September 29, 2002 had exercise prices greater than the average market price of our common stock. These common stock equivalents were outstanding during the three months and nine months ended September 28, 2003 and September 29, 2002 but were excluded from the computation of diluted EPS for those periods because their inclusion would have had an antidilutive effect.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

Also, in the diluted computation, income from continuing operations and net income are reduced by the incremental contribution to the ESOP, acquired as part of the Pharmacia acquisition. This contribution is the after-tax difference between the income that the ESOP would have received in preferred stock dividends and the dividend on the common shares assumed to have been outstanding.

Under GAAP, quarterly EPS computations must stand on their own and therefore, the sum of EPS for each of the first three quarters of 2003 does not equal the EPS for the first nine months of 2003. EPS for the third quarter of 2003 is computed using the weighted average number of common shares outstanding during the quarter while EPS for the first nine months of 2003 is computed using the weighted average number of common shares outstanding during the first nine months of 2003. The weighted average number of common shares outstanding is higher for the third quarter of 2003 than for the first nine months of 2003 as a result of issuing approximately 1.8 billion common shares to complete the Pharmacia acquisition on April 16, 2003. The significant increase in the number of common shares outstanding from the first quarter of 2003 has resulted in our having different bases of shares outstanding and therefore, the EPS results are not additive.

**Note 9: Stock Option and Performance Unit Awards**

In connection with the Pharmacia acquisition on April 16, 2003, we issued approximately 180 million Pfizer stock options in exchange for Pharmacia outstanding stock options. The following table summarizes the activity for our stock and incentive plans related to employees during the first nine months of 2003:

(thousands of shares)	Under Option	
	Shares	Weighted Average Exercise Price Per Share
Balance January 1, 2003	431,981	\$31.45
Pharmacia Option Exchange	180,068	28.84
Granted	101,890	29.78
Exercised	(45,306)	18.59
Cancelled	(31,004)	36.64
Balance September 28, 2003	<u>637,629</u>	31.11

The tax benefits related to certain stock option transactions were \$192 million during the nine months ended September 28, 2003.

**Note 10: Segment Information**

We operate in the following three business segments:

*Pharmaceutical*

- The Pharmaceutical segment includes treatments for cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, infectious and respiratory diseases, urogenital conditions, cancer, eye disease, endocrine disorders and allergies.

*Consumer Healthcare*

- The Consumer Healthcare segment includes self medications for oral care, upper respiratory health, tobacco dependence, gastrointestinal health, skin care, eye care and hair growth.

*Animal Health*

- The Animal Health segment includes treatments for diseases in livestock and companion animals.

We operate several other businesses which include the manufacture of empty soft-gelatin capsules, contract manufacturing, bulk pharmaceutical chemicals and diagnostics. Due to the size of these businesses, they are grouped into the "Other" category.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

Revenues and profits/(losses) by segment for the three months ended September 28, 2003 and September 29, 2002 were as follows:

(in millions)		Pharma- ceutical	Consumer Healthcare	Animal Health	Other <sup>(a)</sup>	Consolidated
Revenues	2003	\$ 11,002	\$ 799	\$ 438	\$ 265	\$ 12,504
	2002	6,996	610	280	110	7,996
Segment profit/(loss)	2003	\$ 2,874	\$ 189	\$ 152	\$ (721) <sup>(b)</sup>	\$ 2,494 <sup>(c)</sup>
	2002	3,074	152	26	(352) <sup>(b)</sup>	2,900 <sup>(c)</sup>

Revenues and profits/(losses) by segment for the nine months ended September 28, 2003 and September 29, 2002 were as follows:

(in millions)		Pharma- ceutical	Consumer Healthcare	Animal Health	Other <sup>(a)</sup>	Consolidated
Revenues	2003	\$ 27,190	\$ 2,135	\$ 1,090	\$ 607	\$ 31,022
	2002	20,031	1,897	794	317	23,039
Segment profit/(loss)	2003	\$ 3,627	\$ 364	\$ 19	\$ (1,698) <sup>(b)</sup>	\$ 2,312 <sup>(c)</sup>
	2002	8,832	451	65	(1,015) <sup>(b)</sup>	8,333 <sup>(c)</sup>

<sup>(a)</sup> Includes Capsugel, Pfizer CentreSource, Diagnostics and Corporate/Other.

<sup>(b)</sup> Includes interest income/(expense), corporate expenses, other income/(expense) of our banking and insurance subsidiaries, certain performance-based compensation expenses not allocated to the operating segments and merger-related costs.

<sup>(c)</sup> Equals income from continuing operations before provision for taxes on income, minority interests and cumulative effect of change in accounting principles. In 2003, segment profit/(loss) includes the impact of purchase accounting for the Pharmacia acquisition.

On July 24, 2003, we announced that we are exploring strategic options for our surgical ophthalmology business, including its possible sale. The surgical ophthalmology business is included in our Pharmaceutical segment and became a part of Pfizer in April 2003 with our acquisition of Pharmacia.

On July 1, 2003, we announced that we are exploring strategic options for the Diagnostics business, including its possible sale. The Diagnostics business became a part of Pfizer in April 2003 with our acquisition of Pharmacia.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

Revenues for each group of similar products are as follows:

(in millions)	Three Months Ended			Nine Months Ended		
	Sept. 28, 2003	Sept. 29, 2002	% Change	Sept. 28, 2003	Sept. 29, 2002	% Change
<b>PHARMACEUTICAL</b>						
Cardiovascular and metabolic diseases	\$ 4,298	\$ 3,429	25	\$ 11,450	\$ 9,761	17
Central nervous system disorders	1,993	1,411	41	5,181	4,056	28
Arthritis and pain	1,078	88	*	1,815	260	598
Infectious and respiratory diseases	1,095	807	36	3,084	2,450	26
Urology	701	437	60	1,700	1,244	37
Oncology	262	--	--	461	--	--
Ophthalmology	310	--	--	441	--	--
Endocrine disorders	216	--	--	323	--	--
All other	940	390	141	2,109	1,139	85
Alliance revenue	109	434	(75)	626	1,121	(44)
Total Pharmaceutical	<u>11,002</u>	<u>6,996</u>	57	<u>27,190</u>	<u>20,031</u>	36
<b>CONSUMER HEALTHCARE</b>	<u>799</u>	<u>610</u>	31	<u>2,135</u>	<u>1,897</u>	13
<b>ANIMAL HEALTH</b>	<u>438</u>	<u>280</u>	56	<u>1,090</u>	<u>794</u>	37
<b>OTHER</b>	<u>265</u>	<u>110</u>	144	<u>607</u>	<u>317</u>	91
Total revenues	<u>\$ 12,504</u>	<u>\$ 7,996</u>	56	<u>\$ 31,022</u>	<u>\$ 23,039</u>	35

\* Change greater than one thousand percent.

Note 11: Discontinued Operations

We sold the following businesses and products that did not fit within our strategic plans:

- In April 2003, we completed the sale of the hormone replacement therapy femhrt, formerly part of our Pharmaceutical segment, to Galen Holdings plc for \$160 million in cash with a right to receive up to \$63.8 million contingent on femhrt retaining market exclusivity until the expiration of its patent. We recognized a gain on the sale of this product of \$139 million (\$83 million net of tax) in the consolidated statement of income for the first nine months of 2003.
- In March 2003, we sold the Adams confectionery products business, formerly part of our Consumer Healthcare segment, to Cadbury Schweppes plc for \$4.2 billion in cash. We recognized a gain on the sale of this business of \$3.091 billion (\$1.824 billion net of tax) in the consolidated statement of income for the first nine months of 2003.
- In March 2003, we sold the Schick-Wilkinson Sword shaving products business, formerly part of our Consumer Healthcare segment, to Energizer Holdings, Inc., for \$930 million in cash. We recognized a gain on the sale of this business of \$462 million (\$262 million net of tax) in the consolidated statement of income for the first nine months of 2003.
- In March 2003, we sold the oral contraceptives Estrostep and Loestrin, formerly part of our Pharmaceutical segment, to Galen Holdings plc for \$197 million in cash with a right to receive up to \$47.3 million contingent on Estrostep retaining market exclusivity until the expiration of its patent. We recognized a gain on the sale of these two products of \$193 million (\$116 million net of tax) in the consolidated statement of income for the first nine months of 2003.

These businesses and product lines are reflected as discontinued operations in all periods presented.

PFIZER INC. AND SUBSIDIARY COMPANIES  
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS  
(UNAUDITED)

The following amounts related to the confectionery, shaving and fish-care product businesses, as well as the femhrt, Loestrin and Estrostep product lines, have been segregated from continuing operations and reflected as discontinued operations:

(in millions)	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
Revenues	\$ <u>(2)</u>	\$ <u>730</u>	\$ <u>763</u>	\$ <u>2,138</u>
Pre-tax income/(loss)	\$ (7)	\$ 130	\$ 46	\$ 330
Provision (benefit) for taxes on income/(loss)	<u>(3)</u>	<u>49</u>	<u>18</u>	<u>123</u>
Income from operations of discontinued businesses/product lines-net of tax	<u>(4)</u>	<u>81</u>	<u>28</u>	<u>207</u>
Pre-tax gains on sales of discontinued businesses	--	--	3,885	--
Provision for taxes on gains	--	--	1,600	--
Gains on sales of discontinued businesses/product lines-net of tax	--	--	2,285	--
Discontinued operations-net of tax	\$ <u>(4)</u>	\$ <u>81</u>	\$ <u>2,313</u>	\$ <u>207</u>

Note 12: Subsequent Events

On October 23, 2003, our board of directors declared a \$.15 per share fourth-quarter 2003 cash dividend on our common stock, payable on December 4, 2003 to shareholders of record on November 14, 2003.

On October 23, 2003, our board of directors approved an amendment to our Shareholders' Rights Plan under which an existing "poison pill" provision will expire at the end of 2003.

## INDEPENDENT ACCOUNTANTS' REVIEW REPORT

To the Shareholders and Board of Directors of Pfizer Inc.:

We have reviewed the condensed consolidated balance sheet of Pfizer Inc. and Subsidiary Companies as of September 28, 2003 and the related condensed consolidated statements of income for the three-month and nine-month periods ended September 28, 2003 and September 29, 2002 and cash flows for the nine-month periods then ended. These condensed consolidated financial statements are the responsibility of the Company's management.

We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States of America, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

We have previously audited, in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet of Pfizer Inc. and Subsidiary Companies as of December 31, 2002, and the related consolidated statements of income, shareholders' equity and cash flows for the year then ended (not presented herein); and in our report dated February 27, 2003, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2002, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

KPMG LLP

New York, New York  
November 12, 2003

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)

The components of the Condensed Consolidated Statement of Income follow:

(in millions, except per common share data)	Third Quarter			First Nine Months		
	2003	2002	% Change	2003	2002	% Change
Revenues	\$ 12,504	\$ 7,996	56	\$ 31,022	\$ 23,039	35
Cost of sales	3,366	1,026	228	6,459	2,867	125
% of revenues	26.9%	12.8%		20.8%	12.4%	
Selling, informational and administrative expenses	4,043	2,657	52	10,560	7,864	34
% of revenues	32.3%	33.2%		34.0%	34.1%	
Research and development expenses	1,879	1,245	51	4,813	3,665	31
% of revenues	15.0%	15.6%		15.5%	15.9%	
Merger-related in-process research and development charge	(87)	--	*	5,043	--	*
% of revenues	(0.7)%	--		16.3%	--	
Merger-related costs	303	114	165	680	387	76
% of revenues	2.4%	1.4%		2.2%	1.7%	
Other (income)/deductions-net	<u>506</u>	<u>54</u>	863	<u>1,155</u>	<u>(77)</u>	*
Income from continuing operations before provision for taxes on income, minority interests and cumulative effect of change in accounting principles	\$ 2,494	\$ 2,900	(14)	\$ 2,312	\$ 8,333	(72)
% of revenues	19.9%	36.3%		7.5%	36.2%	
Provision for taxes on income	\$ 253	\$ 630	(60)	\$ 1,286	\$ 1,859	(31)
Effective tax rate**	10.5%	21.8%		17.5%	22.3%	
Income from continuing operations before cumulative effect of change in accounting principles	\$ 2,239	\$ 2,269	(1)	\$ 1,025	\$ 6,473	(84)
% of revenues	17.9%	28.4%		3.3%	28.1%	
Discontinued operations-net of tax	<u>(4)</u>	<u>81</u>	*	<u>2,313</u>	<u>207</u>	M+
Income before cumulative effect of change in accounting principles	2,235	2,350	(5)	3,338	6,680	(50)
% of revenues	17.9%	29.4%		10.8%	29.0%	
Cumulative effect of change in accounting principles-net of tax	<u>--</u>	<u>--</u>	--	<u>(30)</u>	<u>(410)</u>	*
Net income	<u>\$ 2,235</u>	<u>\$ 2,350</u>	(5)	<u>\$ 3,308</u>	<u>\$ 6,270</u>	(47)
% of revenues	<u>17.9%</u>	<u>29.4%</u>		<u>10.7%</u>	<u>27.2%</u>	
Earnings per common share - Basic:						
Income from continuing operations before cumulative effect of change in accounting principles	\$ .29	\$ .38	(24)	\$ .14	\$ 1.06	(87)
Discontinued operations-net of tax	--	.01	*	.33	.03	*
Cumulative effect of change in accounting principles-net of tax	<u>--</u>	<u>--</u>	--	<u>--</u>	<u>(.07)</u>	*
Net income	<u>\$ .29</u>	<u>\$ .39</u>	(26)	<u>\$ .47</u>	<u>\$ 1.02</u>	(54)
Earnings per common share - Diluted:						
Income from continuing operations before cumulative effect of change in accounting principles	\$ .29	\$ .37	(22)	\$ .14	\$ 1.04	(87)
Discontinued operations-net of tax	--	.01	*	.32	.03	*
Cumulative effect of change in accounting principles-net of tax	<u>--</u>	<u>--</u>	--	<u>--</u>	<u>(.07)</u>	*
Net income	<u>\$ .29</u>	<u>\$ .38</u>	(24)	<u>\$ .46</u>	<u>\$ 1.00</u>	(54)
Cash dividends paid per common share	<u>\$ .15</u>	<u>\$ .13</u>	15	<u>\$ .45</u>	<u>\$ .39</u>	15

Percentages in this table and throughout the MD&A may reflect rounding adjustments.

\* Calculation not meaningful.

\*\* Effective tax rate calculated excluding *Merger-related in-process research and development charge*, which is not tax deductible.

M+ Change greater than one thousand percent.



## OVERVIEW

On April 16, 2003, we acquired all of the outstanding stock of Pharmacia Corporation (Pharmacia) and combined operations as of that date. The acquisition was accounted for as a purchase business combination under accounting principles generally accepted in the United States of America (GAAP). Under the purchase method of accounting, the assets acquired and liabilities assumed from Pharmacia are recorded as of the date of acquisition, at their respective fair values. Reported financial position and results of operations of Pfizer issued after April 16, 2003 (the acquisition date) reflect these values and will not be restated retroactively to reflect the historical financial position or results of operations of Pharmacia. As a result, the fluctuations in our operating results in the three and nine month periods ending September 28, 2003, as compared to the same periods ending September 29, 2002, are generally due to the acquisition of Pharmacia. The results of operations discussed below include Pharmacia's results of operations from the acquisition date. It is important to an understanding of our operating results and financial position to consider that we allocate the purchase price of Pharmacia to the tangible and intangible assets acquired, liabilities assumed, as well as in-process research and development (IPR&D) based on their estimated fair values as of the acquisition date. We engaged an independent third-party appraisal firm to assist us in determining the fair values of assets acquired and liabilities assumed. Such a valuation requires management to make significant estimates and assumptions, especially with respect to intangible assets.

Critical estimates in valuing certain of the intangible assets include but are not limited to: future expected cash flows; expected costs to develop the IPR&D into commercially viable products and estimating cash flows from the projects when completed; and discount rates. Management's estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. Assumptions may be incomplete or inaccurate, and unanticipated events and circumstances may occur.

Estimates associated with the accounting for this acquisition may change as additional information becomes available regarding the assets acquired and liabilities assumed.

## REVENUES

Revenues increased 56% in the third quarter and 35% in the first nine months of 2003, as compared with the prior year periods.

The revenue increases were primarily due to the inclusion of Pharmacia results, strong performances by our in-line products and newly launched products across major businesses and regions, and the weakening of the U.S. dollar relative to other currencies. Effective July 10, 2003, we increased the published prices for certain U.S. pharmaceutical products. These price increases had no effect on end of third quarter 2003 wholesaler inventory levels and are not expected to have a material impact on end of fourth quarter 2003 wholesaler inventory levels. At the end of the second quarter of 2003, Pfizer maintained .5 months supply of pharmaceutical inventory at wholesalers, reflecting our standard historical and ongoing policy of keeping stocking levels under one month on average and keeping monthly levels consistent from year to year based on patterns of utilization. Pharmacia stocking levels began the second quarter of 2003 at a little over 2 months and have been reduced by the end of the third quarter to Pfizer's levels. We essentially completed the harmonization of Pharmacia's trade-inventory practices during the third quarter of 2003. The harmonization of such legacy Pharmacia's trade inventory practices with those of legacy Pfizer negatively impacted revenues by approximately \$200 million for the third quarter and approximately \$500 million for the first nine months of 2003.

Changes in foreign exchange rates increased revenues in the third quarter of 2003 by \$336 million or 4.2% compared to the same period in 2002 and increased revenues in the first nine months of 2003 by \$959 million or 4.2% compared to last year. The foreign exchange impact on the third quarter and first nine months of 2003 revenue growth, relative to the same periods last year, is associated with legacy Pfizer revenues only and primarily reflects the weakening of the U.S. dollar against major currencies. The revenues of legacy Pharmacia products, recorded as of the acquisition date April 16, 2003, do not affect the impact from foreign exchange, given their treatment as incremental volume.

The loss of patent protection with respect to any of our major products, including those described in the Legal Proceedings section, could have a material adverse effect on our projected revenues and net income.

## Revenues by Country

Revenues by country for the third quarter and first nine months and the changes over the prior year were as follows:

(in millions)	Third Quarter				
	2003	% of Revenues	2002	% of Revenues	% Change
United States	\$ 7,226	57.8	\$ 5,072	63.4	42
Japan	767	6.1	485	6.1	58
All other	4,511	36.1	2,439	30.5	85
Consolidated	<u>\$ 12,504</u>	<u>100.0</u>	<u>\$ 7,996</u>	<u>100.0</u>	56

(in millions)	First Nine Months				
	2003	% of Revenues	2002	% of Revenues	% Change
United States	\$ 18,506	59.7	\$ 14,609	63.4	27
Japan	1,821	5.9	1,391	6.0	31
All other	10,695	34.4	7,039	30.6	52
Consolidated	<u>\$ 31,022</u>	<u>100.0</u>	<u>\$ 23,039</u>	<u>100.0</u>	35

## Revenues by Segment

Revenues by segment for the third quarter and the changes over the prior year were as follows:

(in millions)	Third Quarter				
	2003	% of Revenues	2002	% of Revenues	% Change
Pharmaceutical					
U.S.	\$ 6,503	52.0	\$ 4,498	56.3	45
International	4,499	36.0	2,498	31.2	80
Worldwide	<u>11,002</u>	<u>88.0</u>	<u>6,996</u>	<u>87.5</u>	57
Consumer Healthcare					
U.S.	419	3.4	397	4.9	5
International	380	3.0	213	2.7	79
Worldwide	<u>799</u>	<u>6.4</u>	<u>610</u>	<u>7.6</u>	31
Animal Health					
U.S.	211	1.7	132	1.6	60
International	227	1.8	148	1.9	53
Worldwide	<u>438</u>	<u>3.5</u>	<u>280</u>	<u>3.5</u>	56
Other					
U.S.	93	0.7	45	0.6	109
International	172	1.4	65	0.8	169
Worldwide	<u>265</u>	<u>2.1</u>	<u>110</u>	<u>1.4</u>	144
Total	<u>\$ 12,504</u>	<u>100.0</u>	<u>\$ 7,996</u>	<u>100.0</u>	56

Revenues by segment for the first nine months and the changes over the prior year were as follows:

(in millions)	First Nine Months				
	2003	% of Revenues	2002	% of Revenues	% Change
Pharmaceutical					
U.S.	\$16,548	53.3	\$ 12,850	55.8	29
International	10,642	34.3	7,181	31.2	48
Worldwide	<u>27,190</u>	<u>87.6</u>	<u>20,031</u>	<u>87.0</u>	36
Consumer Healthcare					
U.S.	1,207	3.9	1,253	5.4	(4)
International	928	3.0	644	2.8	44
Worldwide	<u>2,135</u>	<u>6.9</u>	<u>1,897</u>	<u>8.2</u>	13
Animal Health					
U.S.	527	1.7	373	1.6	41
International	563	1.8	421	1.8	34
Worldwide	<u>1,090</u>	<u>3.5</u>	<u>794</u>	<u>3.4</u>	37
Other					
U.S.	224	0.8	133	0.6	69
International	383	1.2	184	0.8	108
Worldwide	<u>607</u>	<u>2.0</u>	<u>317</u>	<u>1.4</u>	91
Total	<u>\$31,022</u>	<u>100.0</u>	<u>\$ 23,039</u>	<u>100.0</u>	35

#### Pharmaceutical

Worldwide revenues of the pharmaceutical segment follow:

(in millions)	Third Quarter			First Nine Months		
	2003	2002	% Change	2003	2002	% Change
<b>PHARMACEUTICAL</b>						
Cardiovascular and metabolic diseases	\$ 4,298	\$ 3,429	25	\$ 11,450	\$ 9,761	17
Central nervous system disorders	1,993	1,411	41	5,181	4,056	28
Arthritis and pain	1,078	88	M+	1,815	260	598
Infectious and respiratory diseases	1,095	807	36	3,084	2,450	26
Urology	701	437	60	1,700	1,244	37
Oncology	262	--	--	461	--	--
Ophthalmology	310	--	--	441	--	--
Endocrine disorders	216	--	--	323	--	--
All other	940	390	141	2,109	1,139	85
Alliance revenue	109	434	(75)	626	1,121	(44)
Total Pharmaceutical	<u>\$ 11,002</u>	<u>\$ 6,996</u>	57	<u>\$ 27,190</u>	<u>\$ 20,031</u>	36

M+ Change greater than one thousand percent.

Revenue information for several of our major pharmaceutical products follow:

Product	Category	Third Quarter	
		millions	% Change from 2002
Lipitor	Cardiovascular and metabolic diseases	2,468	22
Norvasc	Cardiovascular and metabolic diseases	1,104	15
Accupril/Accuretic	Cardiovascular and metabolic diseases	179	11
Cardura	Cardiovascular and metabolic diseases	152	15
Glucotrol XL	Cardiovascular and metabolic diseases	92	25
Zoloft	Central nervous system disorders	831	27
Neurontin	Central nervous system disorders	698	23
Geodon	Central nervous system disorders	96	68
Xanax/Xanax XR	Central nervous system disorders	77	--
Aricept*	Central nervous system disorders	67	27
Relpax	Central nervous system disorders	15	88
Celebrex	Arthritis and pain	701	M+
Bextra	Arthritis and pain	236	--
Zithromax	Infectious and respiratory diseases	355	31
Diflucan	Infectious and respiratory diseases	309	10
Viracept	Infectious and respiratory diseases	70	(18)
Zyvox	Infectious and respiratory diseases	61	--
Vfend	Infectious and respiratory diseases	57	362
Viagra	Urology	476	9
Detrol/Detrol LA	Urology	211	--
Camptosar	Oncology	105	--
Ellence	Oncology	81	--
Xalatan/Xalcom	Ophthalmology	254	--
Genotropin	Endocrine disorders	187	--
Zyrtec	All other	347	25
Medrol	All other	92	--
Aricept, Spiriva and Rebif	Alliance revenue	109	(75)**

\* Represents direct sales under license agreement with Eisai Co., Ltd.

\*\* Alliance revenue in 2002 included Celebrex and Bextra under co-promotion agreements with Pharmacia.

M+ Change greater than one thousand percent.

Product	Category	First Nine Months	
		millions	% Change from 2002
Lipitor	Cardiovascular and metabolic diseases	6,583	16
Norvasc	Cardiovascular and metabolic diseases	3,090	11
Accupril/Accuretic	Cardiovascular and metabolic diseases	498	4
Cardura	Cardiovascular and metabolic diseases	427	8
Glucotrol XL	Cardiovascular and metabolic diseases	249	18
Zoloft	Central nervous system disorders	2,220	13
Neurontin	Central nervous system disorders	1,914	20
Geodon	Central nervous system disorders	247	73
Aricept*	Central nervous system disorders	180	22
Xanax/Xanax XR	Central nervous system disorders	141	--
Relpax	Central nervous system disorders	56	451
Celebrex**	Arthritis and pain	1,073	M+
Bextra	Arthritis and pain	421	--
Zithromax	Infectious and respiratory diseases	1,218	31
Diflucan	Infectious and respiratory diseases	856	8
Viracept	Infectious and respiratory diseases	196	(22)
Vfend	Infectious and respiratory diseases	138	M+
Zyvox	Infectious and respiratory diseases	103	--
Viagra	Urology	1,370	10
Detrol/Detrol LA	Urology	310	--
Camptosar	Oncology	216	--
Ellence	Oncology	122	--
Xalatan/Xalcom	Ophthalmology	357	--
Genotropin	Endocrine disorders	276	--
Zyrtec	All other	980	22
Medrol	All other	141	--
Aricept, Bextra, Celebrex, Spiriva and Rebif***	Alliance revenue	626	(44)

\* Represents direct sales under license agreement with Eisai Co., Ltd.

\*\* Includes direct sales under license agreement with Pharmacia prior to the acquisition.

\*\*\* Includes alliance revenue for Bextra and Celebrex under co-promotion agreements with Pharmacia prior to the acquisition.

M+ Change greater than one thousand percent.

**Lipitor**, for the treatment of elevated cholesterol levels in the blood, is the most widely prescribed pharmaceutical product in the world. Despite the challenges of multiple new competitors both in the U.S. and in international markets, we expect that Lipitor's unsurpassed record of cholesterol reduction and patient safety at all doses make it the powerful cholesterol treatment patients and physicians choose most. With 45% of total prescriptions in the U.S. lipid-lowering market year-to-date, Lipitor has gained wide physician and patient acceptance based on its ability to bring the vast majority of patients to target cholesterol goals across the full dosing range. There continues to be an opportunity for further growth of the cholesterol-lowering market. We believe, worldwide, millions of people with high cholesterol are either not diagnosed or not meeting their cholesterol goals with treatment. Evolving treatment guidelines continue to encourage the use of statin therapy. A major clinical trial, the Collaborative Atorvastatin Diabetes Study (CARDS), became the second Lipitor trial to end early because of efficacy. Initial results of this trial showed a significant reduction in heart attacks, strokes and other coronary events in patients with type 2 diabetes with no previous history of heart disease or stroke but with some cardiovascular risk factors other than diabetes. These results will further expand the patient population for Lipitor and reinforce its efficacy and safety profile.

**Norvasc** is the world's most-prescribed branded medicine for treating hypertension and the fourth-largest-selling pharmaceutical in the world.

**Zithromax** is the largest-selling branded antibiotic worldwide. Zithromax was approved by the FDA in May 2002 as the first and only three-day regimen for the treatment of severe acute bacterial symptoms of chronic obstructive pulmonary disease (COPD). In September 2002, we launched the new Zithromax Tri-Pak dosage form (500 mg once daily) in the U.S. In the first quarter of 2002, we launched Zithromax oral suspension as both a single-dose regimen and a three-day regimen for the treatment of acute otitis media (middle ear infection) in pediatric patients and Zithromax IV (for use in a new intravenous delivery device). Zithromax IV was approved in Italy and Spain in the fourth quarter of 2002.

**Diflucan** remains the leading systemic antifungal in the world. Diflucan's sales volume after 14 years on the market reflects the product's continuing acceptance as the therapy of choice for a wide range of fungal infections.

**Viagra**, a treatment for erectile dysfunction, is the world's most recognized pharmaceutical brand and among the most widely prescribed medications. We expect Viagra to continue to dominate the erectile dysfunction market due to its unsurpassed medical profile. Future Viagra sales growth is expected to come from increased patient presentation and physician diagnosis. Direct-to-consumer advertising has been effective in encouraging more men to see a physician and in generating brand loyalty for Viagra.

**Zoloft**, for the treatment of depression, obsessive-compulsive disorder (OCD) in adults and children, panic disorder and post-traumatic stress disorder in adults, is the most-prescribed selective serotonin re-uptake inhibitor (SSRI) in the U.S. In June 2003, the FDA issued an approvable letter to include the safety information from two trials in pediatric depression in the Zoloft package insert. In February 2003, the FDA approved Zoloft for the treatment of social anxiety disorder. In August 2002, Zoloft received labeling in the U.S. featuring the results of the first and only studies assessing the utility of an SSRI in the maintenance treatment of panic disorder and OCD. Zoloft is the only SSRI with labeling for long-term use (up to 25 months) across the above-mentioned anxiety disorders. In May 2002, the FDA approved Zoloft for the treatment of premenstrual dysphoric disorder (PMDD). With the approval for the treatment of PMDD, Zoloft is the antidepressant in the U.S. market with the most approved indications across mood and anxiety disorders.

**Neurontin**, for use in adjunctive therapy for epilepsy, is also approved in more than 60 markets for the treatment of a range of neuropathic pain conditions. In May 2002, the FDA approved Neurontin for the management of post-herpetic neuralgia, which is described as pain in the area affected by a viral infection commonly known as shingles. Neurontin is the first oral medication approved in the U.S. for this condition.

**Geodon**, for the treatment of symptoms associated with schizophrenia, has been approved in 61 countries and launched in Germany, Spain, Brazil, the U.S. and other major markets. The intramuscular (IM) formulation of Geodon was approved by the FDA in June 2002 making it the first atypical or new generation antipsychotic medicine for schizophrenia approved in the U.S. for IM use. Geodon has been approved in Brazil for the treatment of acute mania in bipolar disorder (manic-depressive disorder). A recently completed clinical program supported a U.S. filing for this indication in October 2003. On September 17, Pfizer received an FDA request for a diabetes class warning. On September 19, Pfizer responded to this request by stating that Geodon has not been associated with increased risk for diabetes. Evidence from clinical trials has consistently demonstrated that Geodon has a weight-neutral profile overall. Data also show that Geodon did not adversely affect patients' fasting insulin levels, total cholesterol and triglycerides, and blood sugar levels.

**Zyrtec** provides strong, rapid and long-lasting relief for seasonal and year-round allergies and hives with once-daily dosing. Zyrtec is one of the leading prescribed antihistamines in the U.S. and the only prescription antihistamine with a syrup formulation. In November 2002, the FDA approved Zyrtec for use in children six months of age and older. Zyrtec-D 12 Hour, launched in the third quarter of 2001, is the only prescription oral antihistamine/decongestant combination medicine approved to treat both year-round indoor and outdoor allergies, as well as nasal congestion. Revenue and prescription gains were achieved despite the 28% decline in year-to-date new prescriptions in the antihistamine market due to the availability of multiple over-the-counter (OTC) branded and private-label loratadine (Claritin) products since December 2002. Zyrtec's growth in this declining market can be attributed in part to strong performance in a broad range of formulations--tablets, syrup, and the 12-hour decongestant formulation--and for both adult and pediatric patients.

**Relpax**, a treatment for migraine headaches, was launched in March 2003, as the seventh triptan in the competitive U.S. market (the largest migraine market). Relpax has already surpassed three of its competitors and is achieving more than 6.5% of new prescriptions and strong formulary access. Relpax is currently marketed in 24 countries, including Japan and most of Europe. Launches will continue throughout 2003 and 2004.

**Celebrex**, a COX-2 specific inhibitor, is used for relief of the pain and inflammation of osteoarthritis (OA), adult rheumatoid arthritis (RA), acute pain and primary dysmenorrhea (menstrual pain) in adults. In addition, Celebrex is approved to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP), a rare genetic disease that may result in colorectal cancer, as an adjunct to usual care. Celebrex is the most-prescribed arthritis brand in the U.S. market. In July 2003, marketing authorization for celecoxib (using the brand name Onsenal) for FAP was recommended in Europe. Final approval by the European Union (E.U.) was received in October 2003. With the approval for acute pain and primary dysmenorrhea in the U.S., Celebrex is the COX-2 specific inhibitor approved to treat the broadest range of conditions. In June 2002, the FDA approved revised labeling for Celebrex. The new prescribing information includes additional gastrointestinal safety data and data indicating that there was no increased risk for serious cardiovascular adverse events observed, including heart attack, stroke and unstable angina. We co-promoted Celebrex with Pharmacia prior to our acquisition of Pharmacia on April 16, 2003. Revenue associated with the co-promotion of Celebrex was recorded by us as alliance revenue prior to the acquisition of Pharmacia.

**Bextra** is used for relief of the pain and inflammation of OA, RA and primary dysmenorrhea. Bextra was approved by the FDA in November 2001 and launched in the U.S. in April 2002. Bextra received marketing approval in the E.U. in May 2003 and has been launched broadly throughout Europe, including the U.K. Germany and France, in Canada and across most of Latin America, where the indications include acute pain. We co-promoted Bextra with Pharmacia prior to the acquisition on April 16, 2003. Revenue associated with our co-promotion of Bextra was recorded by us as alliance revenue prior to the acquisition.

**Vfend**, an antifungal, available in both oral and intravenous forms, was launched in July 2002 in the U.S. and in September 2002 in Europe. Vfend is already the leading hospital antifungal product in France and the second-leading hospital antifungal in Germany.

**Viracept**, a treatment for HIV infection in combination with other antivirals, was approved by the FDA in April 2003 for a new dosage form (625 mg). Viracept 625 mg allows patients to take four pills a day rather than ten.

**Xanax/Xanax XR** is a treatment for generalized anxiety disorder (GAD), anxiety associated with depression and panic disorder. Xanax XR is a once-daily, extended-release formulation of Xanax approved by the FDA in January 2003 and was launched in the U.S. in June 2003.

**Zyvox**, a member of the first new class of antibiotics to be introduced in 35 years, has a novel mechanism of action that stops the initial stage of bacterial protein production. Zyvox is available in intravenous, tablet and oral-suspension formulations. In July 2003, Zyvox was approved by the FDA for the treatment of diabetic foot infections caused by Gram-positive bacteria. Zyvox is the first and only oral antibiotic approved for the treatment of methicillin-resistant *Staphylococcus aureus* (drug-resistant bacteria) infections. In December 2002, the FDA approved Zyvox for the treatment of Gram-positive infections in infants and children. European filings are planned for the fourth quarter of 2003.

**Genotropin** is indicated for the long-term treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous growth hormone or due to Prader-Willi Syndrome and for adult patients with growth hormone deficiency. Genotropin is the world's leading recombinant growth hormone. In the U.S., Genotropin is also approved for the long-term treatment of growth failure in children who are born small for gestational age (SGA) and fail to achieve catch-up growth by age two. In July 2003, Genotropin was approved in Europe for children born SGA who failed to show catch-up growth by age four.

**Alliance revenue** reflects revenue associated with the co-promotion of the following products:

**Aricept**, discovered and developed by our alliance partner Eisai Co., Ltd. (Eisai), is the world's leading medicine for the treatment of symptoms of Alzheimer's disease.

**Rebif**, a treatment for multiple sclerosis (MS), discovered and developed by our alliance partner Serono S.A. (Serono), was approved by the FDA and launched in the U.S. in March 2002. Rebif has been shown to decrease the frequency of severe symptoms and delay the accumulation of physical disability associated with relapsing forms of MS. In May 2003, the FDA approved additional efficacy and product-stability information for Rebif's package insert. The FDA also approved label changes related to the temporary storage of Rebif at room temperature. We began co-promoting Rebif in the U.S. in October 2002.

**Spiriva**, discovered and developed by our alliance partner Boehringer Ingelheim, is used to treat Chronic Obstructive Pulmonary Disease (COPD). Spiriva completed mutual recognition in the E.U. in April 2002 and has been introduced in more than 30 countries, including Spain, Canada, Germany and the U.K. While approval is not anticipated in the U.S. before 2004, Boehringer Ingelheim is working with the FDA to make the product available as soon as possible. Spiriva is now recommended as a first-line maintenance treatment for COPD for all stages of disease severity where maintenance treatment appropriate in the latest Global Initiative for Chronic Obstructive Lung Disease guidelines, the most referenced COPD treatment/practice guidelines worldwide.

Alliance revenue also includes revenue associated with our co-promotion of **Celebrex** and **Bextra** under agreements with Pharmacia prior to April 16, 2003, the date we completed our acquisition of Pharmacia.

## Consumer Healthcare

Sales of the Consumer Healthcare segment increased 31% in the third quarter of 2003 and 13% in the first nine months of 2003, as compared with the prior year periods, as follows:

(in millions)	Third Quarter			First Nine Months		
	2003	2002	% Change	2003	2002	% Change
Consumer Healthcare	\$ <u>799</u>	\$ <u>610</u>	31	\$ <u>2,135</u>	\$ <u>1,897</u>	13

The increase in consumer healthcare revenues in the third quarter and first nine months of 2003, as compared to the prior year periods, was primarily due to the inclusion of Pharmacia results as well as:

- the 13% increase in the third quarter of 2003 and 9% increase in the first nine months of 2003 in sales of Listerine mouthwash, which benefited from the recent U.S. launch of Natural Citrus flavor
- the favorable impact of the weakening of the U.S. dollar against major currencies

partially offset by:

- the 3% decline in the third quarter of 2003 and 24% decline in the first nine months of 2003 in sales of Listerine PocketPaks, reflecting the 2002 initial trade stocking as well as a change in demand from initial trial to a more normalized consumption pattern, which has been partially offset by the roll-out to international markets
- the 3% and 7% decline in the third quarter of 2003 and a 4% and 7% decline in the first nine months of 2003 of Benadryl and Sudafed as a result of the loratadine Rx-to-OTC switch
- the divestitures of the Nix and Bonine franchises in North America during the first half of 2003

## Animal Health

Sales of the Animal Health segment increased 56% to \$438 million in the third quarter of 2003 and 37% to \$1,090 million in the first nine months of 2003, as compared with the prior year periods, primarily due to the inclusion of Pharmacia results. Worldwide sales of the major categories of the Animal Health segment were as follows:

(in millions)	Third Quarter			First Nine Months		
	2003	2002	% Change	2003	2002	% Change
Companion animal products	\$ 167	\$ 140	19	\$ 452	\$ 385	17
Livestock products	<u>271</u>	<u>140</u>	93	<u>638</u>	<u>409</u>	56
Total Animal Health	\$ <u>438</u>	\$ <u>280</u>	56	\$ <u>1,090</u>	\$ <u>794</u>	37

Companion animal product revenues increased 19% in the third quarter of 2003 and 17% in the first nine months of 2003, as compared with the prior year periods, with key brand performance as follows:

- Revolution (for protection against fleas and heartworm) sales grew 22% in the third quarter of 2003 and 25% in the first nine months of 2003 due to increased promotional efforts in international markets and the weakening of the U.S. dollar against major currencies
- Clavamox/Synulox (an antibiotic for dogs and cats) sales grew 18% in the third quarter of 2003 and 14% in the first nine months of 2003 due to increased promotional activities in the U.S. and the weakening of the U.S. dollar against major currencies

Livestock product revenues increased 93% in the third quarter of 2003 and 56% in the first nine months of 2003, as compared with the prior year periods, with key performance as follows:

- Swine vaccine sales grew 5% in the third quarter of 2003 and 14% in the first nine months of 2003, as compared with prior year periods, due to the 2002 launches of Flusure (a swine influenza vaccine) in the U.S. and RespiSure One/Stellamune One (a single-dose swine vaccine to prevent pneumonia) in our international markets
- Advocin 180 (an antibiotic used to treat respiratory and internal infections in cattle and swine) which was launched in the U.S. during the fourth quarter of 2002



partially offset by:

- Dectomax (a treatment for internal and external parasites in cattle and swine) sales, which declined 5% in the third quarter and the first nine months of 2003 due primarily to increasing generic competition throughout our markets

## COSTS AND EXPENSES

### Cost of Sales

Cost of sales increased 228% in the third quarter of 2003 and 125% in the first nine months of 2003 as compared with the prior year periods, while revenues increased 56% in the third quarter of 2003 and 35% in the first nine months of 2003. Consistent with purchase accounting, Pharmacia's inventory was recorded on Pfizer's balance sheet at fair value, which was \$3,324 million greater than the carrying value recorded by legacy Pharmacia, and not the actual cost of legacy Pharmacia manufacturing such inventory. As the inventory is sold, the income statement reflects the fair market value of the inventory. Cost of goods sold will be impacted by this markup until the purchased inventory is completely sold. Sales of this inventory are expected to be completed by the end of 2003.

- The impact of the fair-value markup of Pharmacia's inventory on cost of goods sold was \$1,304 million in the third quarter and \$1,712 million in the first nine months of 2003.
- A second factor causing the increase in cost of sales was a change in product mix, given the addition of legacy Pharmacia's product portfolio, which on average has a higher product cost relative to legacy Pfizer's product portfolio.
- A third factor underlying the rate of growth in cost of goods sold was the impact of reflecting cost of goods sold for Celebrex and Bextra after the April 16th acquisition close, compared to reflecting alliance revenue for the co-promotion of Celebrex and Bextra prior to April 16th, which had no cost of goods sold recorded by Pfizer.
- A fourth factor in the increase in cost of goods sold was the unfavorable impact of foreign exchange. This largely stemmed from the weakening of the dollar relative to the euro.

After accounting for these factors, the growth in cost of goods sold was comparable with the growth in revenues.

### Selling, Informational and Administrative Expenses

Selling, informational and administrative expenses increased 52% in the third quarter of 2003 and 34% in the first nine months of 2003, as compared with the prior year periods, mainly due to incremental expenditures associated with the consolidation of Pharmacia-related activity as of the April 16th close of the acquisition, partially offset by initial cost synergies. Marketing expenses of our pharmaceutical products increased 45% in the third quarter of 2003 and 32% in the first nine months of 2003 and included costs associated with the first quarter 2003 U.S. launch of the migraine product Relpax and continued commercial support for products recently launched in the U.S. including the anti-arthritis product Bextra (co-promoted with Pharmacia in the U.S. prior to the acquisition), the antifungal agent Vfend, and the multiple sclerosis product Rebif (co-promoted with Serono in the U.S.). In Europe, the recent launches of Spiriva for COPD (co-promoted with Boehringer Ingelheim) and Relpax also contributed to the period over period increase in marketing expenses.

### Research and Development Expenses

Research and development (R&D) expenses increased 51% in the third quarter of 2003 and 31% in the first nine months of 2003, as compared with the prior year periods. Year over year growth for third quarter and first nine months R&D spending is attributable to the incremental expenditures associated with the consolidation of Pharmacia-related activity as of the April 16th close of the acquisition and increased support of the late-stage development portfolio.

We continue to invest in R&D to provide future sources of revenue through the development of new products, as well as through additional uses for existing in-line and alliance products. However, there are no assurances as to when, or if, we will receive regulatory approval for these or any of our new products. We expect our R&D expenditures for 2003 to be approximately \$7 billion.

### Pending U.S. New Drug Applications (NDAs) and Supplemental Filings:

Product	Indication	Date Submitted
pregabalin	Neuropathic pain, add-on epilepsy and Generalized Anxiety Disorder (GAD)	October 2003
Geodon	Acute mania in bipolar disorder Oral suspension for use in schizophrenic patients who cannot take a capsule	October 2003 September 2002
Detrol	Pediatric patients with neurogenic bladder (loss of control of urination)	October 2003
Depo-Provera	Subcutaneous formulation for contraception	June 2003
Viracept	Use in children with HIV	June 2003
Zyrtec	Chewable tablets	May 2003
Zithromax	Sinusitis	March 2003
Caduet	Single product that combines cholesterol-lowering and antihypertensive medications in Lipitor and Norvasc	March 2003
Vfend	Use to treat fungal infections caused by Candida spp. Powder formulation for oral suspension	June 2003 March 2003
Fragmin	Use to prevent the formation of venous blood clots	February 2003
Spiriva	Chronic Obstructive Pulmonary Disease (COPD)	December 2001
Norvasc	Use in children	September 2001
Cardura XL	Benign prostatic hyperplasia (enlarged prostate)	April 2001

- In October 2003, Inspra was approved in the U.S. for the treatment of heart failure after a heart attack. Inspra will be commercially available in December 2003. The product was also filed in the European Union (E.U.) during the third quarter of 2003.
- In July 2003, the FDA issued a non-approvable letter for the liquid oral suspension dosage form of Geodon. We have responded to the FDA's questions and are working with the FDA to resolve the issues identified.
- In July 2003, the FDA approved the use of Zyvox for diabetic foot infections.
- In June 2003, we submitted a filing in Japan for the use of Zithromax in the treatment of a sexually transmitted disease.
- Also in June 2003, we submitted a filing in Japan for the use of Vfend in the treatment of serious fungal infections, including aspergillus, candida spp. and cryptococcus.
- In March 2003, a filing for pregabalin, for the treatment of neuropathic pain and adjunctive therapy in epilepsy, was submitted in the E.U. We are awaiting additional comparative data as required in the E.U. to provide further support for the E.U. filing submission of pregabalin for GAD.
- In February 2003, Zoloft was approved to treat Social Anxiety Disorder. Several countries in the E.U. have also approved the new indication.
- In December 2002, Spiriva received an approvable letter from the FDA for the long-term once-daily maintenance treatment of bronchospasm associated with COPD. Approval in the U.S. is not expected before 2004. The E.U. Mutual Recognition procedure was completed in April 2002.
- In 2002, our co-marketing partner Eisai submitted supplemental filings in the U.S. and the E.U. for the use of Aricept in the treatment of vascular dementia (VaD). In June 2003, the FDA issued a non-approvable letter for the use of Aricept in the treatment of VaD.

**Ongoing or planned clinical trials for additional uses and dosage forms for our products include:**

<b>Product</b>	<b>Indication</b>
Viagra	Female sexual arousal disorder Pulmonary arterial hypertension in both children and adults
Celebrex	Sporadic adenomatous polyposis--a precancerous condition caused by growths in the intestines Bladder cancer Barrett's esophagus--a precancerous condition caused by repeated damage from stomach acid regurgitation Actinic keratosis--a precancerous skin growth caused by overexposure to sunlight Ankylosing spondylitis--an inflammation of the spine Chronic low back pain
Depo Provera	Injectable formulation to treat endometriosis
Zoloft	Depression with acute myocardial infarction or unstable angina
Bextra	Acute pain Migraine
Zithromax	Sustained release Zithromax (bacterial infections) Cystic fibrosis
Camptosar IV	Use in children Adjuvant colorectal cancer Gastric cancer
Diflucan	Use in children
Detrol	Treatment of incontinence in children
Fragmin	Use in oncology patients to reduce cardiac toxicity associated with chemotherapy
Zyvox	Use for penicillin-resistant <i>Streptococcus pneumoniae</i> infections in patients with pneumonia

Advanced-stage clinical studies are continuing for several agents including:

- indiplon for the treatment of insomnia, under co-development with Neurocrine Biosciences, Inc. (Neurocrine)
- Macugen for age related macular degeneration and macular edema, under co-development with Eyetech Pharmaceuticals, Inc. (Eyetech)
- capravirine for resistant forms of HIV/AIDS
- SU-11248 (an anti-cancer compound) for gastrointestinal stromal cell tumors and renal carcinoma
- edotecarin (an anti-cancer compound) for glioblastoma (brain tumors)
- lasofoxifene for osteoporosis and other indications
- varenicline for smoking cessation
- Exubera, an inhalable form of insulin under co-development, co-manufacture, and co-marketing with Aventis Pharma (Aventis), with the participation of Nektar Therapeutics
- Dynastat, an injectable COX-2 inhibitor for pain and inflammation
- Lipitor-torcetrapib combination therapy for markedly lowering LDL cholesterol and markedly raising HDL cholesterol

- roflumilast for COPD and asthma under co-development with Altana Pharma
- CDP-870 for rheumatoid arthritis under co-development with Celltech Group plc
- Zithromax/chloroquine combination for malaria
- sumanirole for Parkinson's disease

Together with Aventis, we are completing additional long-term safety studies for the Exubera development program. These trials are well under way and involve patients with Type 1 and Type 2 diabetes. Because of the potential widespread use of Exubera among diabetes patients, additional rigorous testing and assessment of all pulmonary function measures are appropriate to deepen the medical understanding of diabetes and Exubera's role in the future management of diabetes. Based on interim data from one-year controlled safety studies, we are confident that Exubera will be an important medication to treat this devastating disease. We are continuing our discussions with regulatory agencies regarding the timing of the submission in both the U.S. and the E.U.

In December 2002, we announced an agreement with Neurocrine for the exclusive worldwide development and commercialization of indiplon, Neurocrine's Phase III compound for the treatment of insomnia. Under terms of the agreement, we will obtain an exclusive, worldwide license for indiplon. We will record all sales of indiplon. Neurocrine will have exclusive rights to co-promote, but not to sell, indiplon in the U.S. Following filing of an NDA for indiplon, Neurocrine will also have rights to detail, but not sell, our antidepressant Zoloft, in the U.S., and would earn a fee for such detailing efforts equal to a percentage of Zoloft sales in the U.S. that are above a baseline threshold. The government approved the transaction in February 2003 and we expensed a payment of \$100 million, included in *Other (income)/deductions-net*, to Neurocrine in the first quarter of 2003. Additional milestone payments of \$300 million potentially could be made to Neurocrine based on worldwide regulatory submissions and approvals. We will fund the ongoing development of indiplon and pay royalties on worldwide sales and co-promotion commissions in the U.S. Neurocrine plans to submit the indiplon NDA in the first half of 2004. Following the U.S. launch of indiplon, we will provide to Neurocrine a \$175 million secured credit facility for a period of three years.

Also in December 2002, we announced an agreement with Eyetech to jointly develop and commercialize Eyetech's Macugen(TM) (pegaptanib sodium), a treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME), both leading causes of blindness. The government approved the transaction in February 2003 and we expensed a \$100 million payment, included in *Other (income)/deductions-net*, to Eyetech in the first quarter of 2003. Additional milestone payments up to \$195.5 million potentially could be made to Eyetech based on worldwide regulatory submissions and approvals. Eyetech also has the potential to receive up to an additional \$450 million in milestone payments, which are contingent upon successful commercialization of Macugen(TM) and attainment of agreed-upon sales levels. We will also fund the majority of the ongoing development costs for both the AMD and DME indications. If approved, we will co-promote Macugen(TM) with Eyetech in the U.S. and we will record alliance revenue for co-promotion services provided to Eyetech. Outside the U.S., we will market the product exclusively under a royalty-bearing license and we will directly record sales of the product.

In April 2003, we announced an agreement with Daiichi Pharmaceutical Co., Ltd. and obtained an exclusive license for DK-507k, a new quinolone antibiotic for both oral and intravenous administration to treat respiratory-tract and other infections. The product is currently in Phase I clinical trials. Pfizer is currently reviewing whether or not to proceed with development.

On October 20, 2003, Pfizer announced a global agreement to collaborate with Organon, the human pharmaceutical business unit of Akzo Nobel, for the exclusive worldwide development and commercialization of asenapine, a 5HT<sub>2</sub>/D<sub>2</sub> antagonist beginning Phase 3 trials for schizophrenia and bipolar disorder. Under terms of the agreement, the companies will collaborate on the clinical development and manufacturing of asenapine and copromote the product in the U.S., E.U., Japan, and other markets. Pfizer will make an initial payment of \$100 million (which will be expensed) and up to \$270 million in milestone payments contingent upon regulatory approvals and launch of asenapine in the U.S., E.U., and Japan as well as the attainment of certain agreed upon sales levels. If approved, we will co-promote asenapine with Organon and we will record alliance revenue for co-promotion services provided to Organon.

Additional product-related programs are in various stages of discovery and development.

## MERGER-RELATED IN-PROCESS RESEARCH AND DEVELOPMENT CHARGE

As required by Financial Accounting Standards Board Interpretation No. 4, *Applicability of FASB Statement No. 2 to Business Combinations Accounted for by the Purchase Method* (FIN 4), we recorded a charge of \$5,043 million in the first nine months ended September 28, 2003 (reflects a credit of \$87 million recorded in the third quarter of 2003 to adjust our estimate) for the preliminary estimate of the portion of the purchase price allocated to in-process research and development. A project-by-project valuation is being performed by independent valuation specialists to determine the fair value of research and development projects of Pharmacia which were in-process, but not yet completed. The final valuation is expected to be completed as soon as possible but no later than one year from the acquisition date. To the extent that our estimates need to be adjusted, we will do so.

## MERGER-RELATED COSTS

We incurred the following merger-related costs in connection with our merger with Warner-Lambert Company (Warner-Lambert) which was completed on June 19, 2000 and our acquisition of Pharmacia which was completed on April 16, 2003:

(in millions)	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
Integration costs - Warner-Lambert	\$ 2	\$ 99	\$ 23	\$ 276
Integration costs - Pharmacia	251	1	552	1
Restructuring charges - Warner-Lambert	(4)	14	(1)	110
Restructuring charges - Pharmacia	54	--	106	--
Total merger-related costs	<u>\$ 303</u>	<u>\$ 114</u>	<u>\$ 680</u>	<u>\$ 387</u>

Integration costs represent external, incremental costs directly related to our merger with Warner-Lambert and acquisition of Pharmacia, including expenditures for consulting and systems integration.

### *Restructuring Charges - Warner-Lambert*

The components of the restructuring charges associated with the merger of the Warner-Lambert operations follow:

(in millions)	<u>Provisions</u>					Utilization Through Sept. 28, 2003	Reserve* Sept. 28, 2003
	Year 2000	Year 2001	Year 2002	Nine Months Ended Sept. 28, 2003	Total		
Employee termination costs	\$ 850	\$ 249	\$ 170	\$ (1)	\$ 1,268	\$ (1,260)	\$ 8
Property, plant and equipment	46	84	4	--	134	(134)	--
Other	21	30	13	--	64	(64)	--
	<u>\$ 917</u>	<u>\$ 363</u>	<u>\$ 187</u>	<u>\$ (1)</u>	<u>\$ 1,466</u>	<u>\$ (1,458)</u>	<u>\$ 8</u>

\*Included in *Other current liabilities*.

Through September 28, 2003, the charges for employee termination costs represent the approved reduction of our work force of our continuing businesses by 8,067 people, mainly in administrative functions for corporate, manufacturing, distribution, sales and research. We notified affected individuals and as of September 28, 2003, 7,697 employees were terminated.

Employee termination costs include accrued severance benefits and costs associated with change-in-control provisions of certain Warner-Lambert employment contracts. Under the terms of Warner-Lambert employment contracts, certain terminated employees may elect to defer receipt of severance benefits. Severance benefits deferred for future payments were \$230 million at September 28, 2003 and \$218 million at December 21, 2002. The deferred severance benefits are considered utilized charges and are included in *Other noncurrent liabilities* in the condensed balance sheet.

### *Restructuring Charges - Pharmacia*

During the second and third quarters of 2003, in connection with the acquisition of Pharmacia, Pfizer management approved and initiated plans to restructure the operations of both legacy Pfizer and legacy Pharmacia to eliminate duplicative facilities and reduce costs.

We recorded \$106 million of restructuring costs associated primarily with exiting certain activities of legacy Pfizer, including severance, costs of vacating duplicative facilities and contract termination costs. These costs have been recorded as a charge to the results of operations through the nine months ended September 28, 2003 and are included in *Merger-related costs*. The components of the restructuring charges associated with the acquisition of Pharmacia which were expensed in 2003 follow:

	Provisions		Utilization Through Sept. 28, 2003	Reserve* Sept. 28, 2003
	Nine Months Ended Sept. 28, 2003	Total		
(in millions)				
Employee termination costs	\$ 76	\$ 76	\$ (44)	\$ 32
Asset impairments	15	15	(15)	--
Other	15	15	(4)	11
	<u>\$ 106</u>	<u>\$ 106</u>	<u>\$ (63)</u>	<u>\$ 43</u>

\*Included in *Other current liabilities*.

Through September 28, 2003, the charges for employee termination costs represent the approved reduction of the legacy Pfizer work force by 865 people, mainly in administrative functions for corporate, manufacturing, distribution, sales and research. We notified affected individuals and as of September 28, 2003, 706 employees were terminated. Asset impairments primarily include charges to write-down property, plant and equipment. Other primarily includes costs to exit certain activities of legacy Pfizer.

#### *Pharmacia Acquisition-Related Restructuring Costs Capitalized in 2003 as a Cost of the Acquisition*

We recorded \$1,319 million of similar restructuring costs associated primarily with exiting certain activities of legacy Pharmacia. These costs are accounted for under Emerging Issues Task Force (EITF) Issue No. 95-3, *Recognition of Liabilities in Connection with Purchase Business Combinations*, and were recognized as a liability assumed in the purchase business combination. Accordingly, these costs were included in the allocation of the cost to acquire Pharmacia and have been recorded as an increase to goodwill. In accordance with EITF 95-3, these restructuring costs also include costs associated with relocation. The restructuring liabilities are included in *Other current liabilities*. The components of the restructuring costs capitalized in 2003 as a cost of the acquisition of Pharmacia follow:

	Costs Incurred		Utilization Through Sept. 28, 2003	Reserve Sept. 28, 2003
	Nine Months Ended Sept. 28, 2003	Total		
(in millions)				
Employee termination costs	\$ 1,065	\$ 1,065	\$ (742)	\$ 323
Asset impairments	27	27	(27)	--
Relocation costs	96	96	(24)	72
Other	131	131	(11)	120
	<u>\$ 1,319</u>	<u>\$ 1,319</u>	<u>\$ (804)</u>	<u>\$ 515</u>

Through September 28, 2003, the employee termination costs represent the approved reduction of the legacy Pharmacia work force by 9,425 people, mainly in corporate, manufacturing, distribution, sales and research. We notified affected individuals and as of September 28, 2003, 8,271 employees were terminated. Employee termination costs include accrued severance benefits and costs associated with change in control provisions of certain Pharmacia employment contracts. Asset impairments primarily include charges to write-down property, plant and equipment. Other includes costs to exit certain activities of legacy Pharmacia.

Changes to the estimates of completing the currently approved restructuring plans or costs related to new restructuring initiatives will be recorded in results of operations for legacy Pfizer and will be recorded in goodwill for legacy Pharmacia for one year following the acquisition date of April 16, 2003.

### Other (income)/deductions-net

The following components were included in *Other (income)/deductions-net* for the third quarter and first nine months of 2003 and 2002:

(in millions)	Third Quarter			First Nine Months		
	2003	2002	% Change	2003	2002	% Change
Interest income	\$ (89)	\$ (95)	(6)	\$ (267)	\$ (279)	(4)
Interest expense	64	73	(12)	185	185	--
Amortization of finite-lived intangibles	4	3	33	6	24	(75)
Foreign exchange	9	36	(75)	3	38	(92)
Co-promotion charges and intellectual property rights payments	--	10	--	280	32	775
Various litigation matters	--	25	--	33	25	32
Amortization of finite-lived intangibles--purchase-accounting related	606	--	--	1,177	--	--
Other purchase-accounting related items	(9)	--	--	(16)	--	--
Gains on the sales of products	(11)	--	--	(87)	(20)	335
Charges to write-down equity investments	--	28	--	8	28	(71)
Other, net	(68)	(26)	162	(167)	(110)	52
Other (income)/deductions-net	<u>\$ 506</u>	<u>\$ 54</u>	863	<u>\$ 1,155</u>	<u>\$ (77)</u>	*

\* Calculation not meaningful.

*Other income/(deductions)-net* reflects a significant increase in expenses for the third quarter and first nine months of 2003 principally due to \$606 and \$1,177 million in amortization of identifiable intangibles associated with the acquisition of Pharmacia. Consistent with purchase accounting, intangible assets are reflected on Pfizer's balance sheet at fair value. The income-statement impact reflects the amortization of these assets over their estimated useful lives (e.g., until patent expiration for a currently marketed product).

### TAXES ON INCOME

The estimated effective tax rate (ETR) used in calculating full-year 2003 income from continuing operations before cumulative effect of change in accounting principles is 36.3%. The projected full-year 2003 ETR is higher than the 22.1% ETR used in calculating full-year 2002 income from continuing operations before cumulative effect of change in accounting principles primarily due to the impact of purchase accounting for the Pharmacia acquisition.

### ADJUSTED INCOME

We believe investors' understanding of our performance is enhanced by disclosing adjusted income, defined as net income excluding the impact of purchase accounting for the Pharmacia acquisition, certain significant items, merger-related costs and the cumulative effect of change in accounting principles. Management analyzes the company's performance on this basis.

We have excluded the impact of significant purchase-accounting impacts related to our acquisition of Pharmacia. These impacts primarily relate to the one-time charge for purchased in-process research and development, the charges to cost of goods sold from the workdown of purchased inventory that was written up to fair value, and the charges related to the amortization of Pharmacia finite-lived intangible assets, as well as the incremental depreciation of fixed assets for the increase to fair value. We believe that excluding these non-cash charges provides a better view of our economic performance.

The Company also excludes "certain significant items" from adjusted income in order to better portray its major operations--the discovery, development, manufacture, marketing, and sale of market-leading prescription medicines for humans and animals, as well as many of the world's best-known over-the-counter products. For example, we exclude gains or losses on the sale of product lines or discontinued businesses. While we review our businesses and product lines on an ongoing basis for strategic fit with our operations, we do not build or run our businesses with an intent to sell them and, therefore, we have excluded such gains or losses on sales of businesses or product lines from adjusted income. Another example of an excluded "certain significant item" is co-promotion charges and payments for intellectual property rights for unapproved products being developed by third parties, which are immediately expensed rather than amortized over the life of the agreement. Since such payments are expensed immediately, excluding such payments from our economic performance provides us with a better view of our operations. We exclude charges related to various litigation matters from adjusted income as they relate to significant settlement of legal matters. We also exclude gains/losses from the sale or writedown of equity investments from

adjusted income. Generally, these investments are made in biotech companies on an opportunistic basis and are not part of our ongoing internal discovery and development programs.

While we continually look for improvement opportunities within our businesses and reorganize when necessary, at times we will perform a review for restructuring an area of our business. During 2003, our research division undertook such a review and began to initiate its restructuring plan in the second quarter of 2003. The last time that such a restructuring occurred in this division, with the exception of our acquisition-related restructurings, was in 1993. As such, we have excluded the charges of these activities from adjusted income.

In 2000 we acquired Warner-Lambert, and in April 2003 we acquired Pharmacia Corporation. These acquisitions have significant integration and restructuring costs attendant to them. We have excluded these costs from adjusted income, because integration and restructuring costs are unique to these transactions and will occur over several years due to the global and highly regulated nature of our business.

A reconciliation between net income, as reported under GAAP, and adjusted income follows:

(in millions)	Third Quarter			First Nine Months		
	2003	2002	% Incr./ (Decr.)	2003	2002	% Incr./ (Decr.)
Reported net income	\$ 2,235	\$ 2,350	(5)	\$ 3,308	\$ 6,270	(47)
Purchase accounting adjustments-net of tax	1,279	--	*	7,139	--	*
Certain significant items and merger-related costs-net of tax	122	102	20	(1,723)	292	*
Cumulative effect of change in accounting principles-net of tax	--	--	--	30	410	*
Adjusted income	<u>\$ 3,636</u>	<u>\$ 2,452</u>	48	<u>\$ 8,754</u>	<u>\$ 6,972</u>	26

\*Calculation not meaningful.



Adjusted income as shown above excludes the following items:

(in millions)	Third Quarter		First Nine Months	
	2003	2002	2003	2002
<i>Significant items, pre-tax:</i>				
Gains on sales of discontinued businesses/product lines <sup>(a)</sup>	\$ --	\$ --	\$ (3,885)	\$ --
Merger-related and exit costs of discontinued businesses <sup>(a)</sup>	7	--	15	3
Gains on sales of products <sup>(b)</sup>	(11)	--	(87)	(20)
Co-promotion charges and intellectual property rights payments <sup>(b)</sup>	--	10	280	32
Charges to write-down equity investments <sup>(b)</sup>	--	28	8	28
Various litigation matters <sup>(c)</sup>	--	25	33	25
Restructuring charges <sup>(d)</sup>	19	--	40	--
Total significant items	<u>15</u>	<u>63</u>	<u>(3,596)</u>	<u>68</u>
<i>Merger-related costs, pre-tax:</i>				
Integration costs--Warner-Lambert	2	99	23	276
Integration costs--Pharmacia	251	1	552	1
Restructuring charges--Warner-Lambert	(4)	14	(1)	110
Restructuring charges--Pharmacia	54	--	106	--
Total merger-related costs	<u>303</u>	<u>114</u>	<u>680</u>	<u>387</u>
Total significant items and merger-related costs, pre-tax	<u>318</u>	<u>177</u>	<u>(2,916)</u>	<u>455</u>
Income taxes	(196)	(75)	1,193	(163)
Total significant items and merger-related costs-net of tax	<u>122</u>	<u>102</u>	<u>(1,723)</u>	<u>292</u>
<i>Purchase accounting adjustments, pre-tax:</i>				
In-process research and development <sup>(e)</sup>	(87)	--	5,043	--
Work down of inventory write-up to fair value <sup>(f)</sup>	1,304	--	1,712	--
Intangible amortization/fixed asset depreciation <sup>(g)</sup>	703	--	1,299	--
Total purchase accounting adjustments, pre-tax	<u>1,920</u>	<u>--</u>	<u>8,054</u>	<u>--</u>
Income taxes	(641)	--	(915)	--
Total purchase accounting adjustments-net of tax	<u>1,279</u>	<u>--</u>	<u>7,139</u>	<u>--</u>
Cumulative effect of change in accounting principles-net of tax	<u>--</u>	<u>--</u>	<u>30</u>	<u>410</u>
Total significant items, merger-related costs, purchase accounting adjustments and cumulative effect of change in accounting principles-net of tax	<u>\$ 1,401</u>	<u>\$ 102</u>	<u>\$ 5,446</u>	<u>\$ 702</u>

(a) Included in *Discontinued operations-net of tax*.

(b) Included in *Other (income)/deductions-net*.

(c) Included in *Other (income)/deductions-net* for the first nine months of 2003 and in *Selling, informational and administrative expenses* (\$10 million) and in *Other (income)/deductions-net* (\$15 million) for the third quarter and first nine months of 2002.

(d) Included in *Research and development expenses*.

(e) Included in *Merger-related in-process research and development charge*.

(f) Included in *Cost of sales*.

(g) Included in *Cost of sales* (\$40 million and \$64 million); *Selling, informational and administrative expenses* (\$18 million and \$33 million); *Research and development expenses* (\$48 million and \$41 million); and *Other (income)/deductions-net* (\$597 million and \$1,161 million) for the third quarter and first nine months of 2003.

We sold the following businesses and products that do not fit our strategic goals:

- In April 2003, we completed the sale of the hormone replacement therapy femhrt, formerly part of our Pharmaceutical segment, to Galen Holdings plc for \$160 million in cash with a right to receive up to \$63.8 million contingent on femhrt retaining market exclusivity until the expiration of its patent. We recognized a gain on the sale of this product of \$139 million (\$83 million net of tax) in the consolidated statement of income for the first nine months of 2003.
- In March 2003, we sold the Adams confectionery products business, formerly part of our Consumer Healthcare segment, to Cadbury Schweppes plc for \$4.2 billion in cash. We recognized a gain on the sale of this business of \$3.091 billion (\$1.824 billion net of tax) in the consolidated statement of income for the first nine months of 2003.
- In March 2003, we sold the Schick-Wilkinson Sword shaving products business, formerly part of our Consumer Healthcare segment, to Energizer Holdings, Inc., for \$930 million in cash. We recognized a gain on the sale of this

business of \$462 million (\$262 million net of tax) in the consolidated statement of income for the first nine months of 2003.

- In March 2003, we sold the oral contraceptives Estrostep and Loestrin, formerly part of our Pharmaceutical segment, to Galen Holdings plc for \$197 million in cash with a right to receive up to \$47.3 million contingent on Estrostep retaining market exclusivity until the expiration of its patent. We recognized a gain on the sale of these two products of \$193 million (\$116 million net of tax) in the consolidated statement of income for the first nine months of 2003.

These businesses and product lines are reflected as discontinued operations in all periods presented.

The following amounts related to the confectionery, shaving and fish-care product businesses, as well as the femhrt, Loestrin and Estrostep product lines, have been segregated from continuing operations and reflected as discontinued operations:

(in millions)	Three Months Ended		Nine Months Ended	
	Sept. 28, 2003	Sept. 29, 2002	Sept. 28, 2003	Sept. 29, 2002
Revenues	\$ (2)	\$ 730	\$ 763	\$ 2,138
Pre-tax income/(loss)	\$ (7)	\$ 130	\$ 46	\$ 330
Provision(benefit) for taxes on income/(loss)	(3)	49	18	123
Income from operations of discontinued businesses/product lines-net of tax	(4)	81	28	207
Pre-tax gains on sales of discontinued businesses/product lines	--	--	3,885	--
Provision for taxes on gains	--	--	1,600	--
Gains on sales of discontinued businesses/product lines-net of tax	--	--	2,285	--
Discontinued operations-net of tax	\$ (4)	\$ 81	\$ 2,313	\$ 207

#### FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

Our net financial asset position was as follows:

(in millions)	Sept. 28, 2003	Dec. 31, 2002
Financial assets*	\$ 20,719	\$ 18,111
Short-term borrowings and long-term debt	15,835	11,809
Net financial assets	\$ 4,884	\$ 6,302

\* Consists of cash and cash equivalents, short-term loans and investments and long-term loans and investments.

Selected measures of liquidity and capital resources:

	Sept. 28, 2003	Dec. 31, 2002
Cash and cash equivalents and short-term loans and investments (millions of dollars)*	\$ <u>14,757</u>	\$ <u>12,950</u>
Working capital (millions of dollars)**	\$ <u>11,407</u>	\$ <u>6,226</u>
Current ratio***	<u>1.53:1</u>	<u>1.34:1</u>
Shareholders' equity per common share+	\$ <u>8.94</u>	\$ <u>3.27</u>

\* Wherever possible, cash management is centralized and intercompany financing is used to provide working capital to subsidiaries as needed. Where local restrictions prevent intercompany financing, subsidiaries' working capital needs would be met through ongoing cash flows and/or external borrowings.

\*\* We rely largely on operating cash flow, short-term commercial paper borrowings and long-term debt to provide for working capital needs. Working capital includes assets and liabilities of discontinued businesses held for sale at December 31, 2002.

\*\*\* Current ratio is the proportion of current assets to current liabilities.

+ Represents total shareholders' equity divided by the actual number of common shares outstanding (which excludes treasury shares and those held by our employee benefit trust).

The increase in working capital from December 31, 2002 to September 28, 2003 primarily reflects:

- cash from current period operations
- cash receipts from long-term debt issuances -- \$600 million
- acquisition of the assets and assumption of liabilities of Pharmacia on April 16, 2003

partially offset by:

- purchases of property, plant and equipment -- \$1,862 million
- purchases of our common stock -- \$9,873 million
- cash dividends on common and preferred stock -- \$3,276 million

The increase in shareholders' equity per common share is primarily due to the acquisition of Pharmacia.

#### Net Cash Provided by Operating Activities

During the first nine months of 2003, net cash provided by continuing operating activities was \$7,329 million, as compared to \$6,261 million in the 2002 period. The change in net cash provided by operating activities in 2003 was primarily due to the inclusion of Pharmacia operations from April 16, 2003, the date of acquisition.

#### Net Cash Provided by/(Used in) Investing Activities

During the first nine months of 2003, net cash provided by investing activities of \$3,939 million, as compared to net cash used in investing activities of \$3,702 million in the 2002 period. The change in net cash provided by/(used in) investing activities in 2003 was primarily attributable to:

- proceeds from the sales of businesses and product lines (an increase of \$5,594 million)
- cash and cash equivalents acquired in the Pharmacia acquisition (\$1,789 million)
- a decline in net purchases of short-term and long-term investments (a decrease of \$1,320 million)

partially offset by:

- increased purchases of property, plant and equipment (an increase of \$690 million)

#### Net Cash Used in Financing Activities

During the first nine months of 2003 net cash used in financing activities was \$11,524 million, as compared to \$1,956 million in the 2002 period. The change in net cash used in financing activities in 2003 was primarily attributable to:

- an increase in cash dividends paid (an increase of \$894 million)
- an increase in common share purchases (an increase of \$5,147 million)
- a decrease in net borrowings (a decrease of \$3,905 million)

partially offset by:

- an increase in stock options exercised (an increase of \$339 million)

In February 2003, we issued:

- \$300 million senior unsecured notes, due March 2009, which pay interest semi-annually, beginning on September 2, 2003, at a rate of 3.3%; and
- \$300 million senior unsecured notes, due March 2018, which pay interest semi-annually, beginning on September 1, 2003, at a rate of 4.65%.

The notes were issued under a \$5 billion debt shelf registration statement filed with the Securities and Exchange Commission in November 2002.

In June 2002, we announced a new authorization to purchase up to \$10 billion of the Company's common stock. This program was subsequently increased to authorize the Company and its affiliates to purchase up to \$16 billion of common stock. Since inception of this program, approximately 408 million shares have been purchased under this authorization through September 28, 2003, at a total cost of about \$12.9 billion, including 306 million shares purchased during 2003 at a total cost of about \$9.9 billion. A total of 460 million shares have been purchased through October 22, 2003 at a total cost of \$14.5 billion. The remaining \$1.5 billion of this authorization is expected to be completed in the fourth quarter of 2003. Purchased shares are available for general corporate purposes.

We have available lines of credit and revolving-credit agreements with a group of banks and other financial intermediaries. We utilize short-term commercial paper to provide working capital. We maintain cash balances in excess of our commercial paper borrowings and have access to \$2.9 billion of lines of credit of which \$2.4 billion expire within one year. Of these lines of credit, approximately \$2.4 billion are unused, of which our lenders have committed to loan us \$1.0 billion at our request.

Legacy Pharmacia guaranteed certain transactions in which Monsanto, its former agricultural subsidiary, is involved. These guarantees continued after Pfizer's acquisition of Pharmacia and at September 28, 2003 included approximately \$310 million of bank notes with maturities not later than 2004 and \$5 million of environmental guarantees, which are required until Monsanto can obtain certain approvals.

#### Pharmacia Acquisition

On April 16, 2003, Pfizer acquired Pharmacia for a purchase price of approximately \$56 billion, which includes Pfizer common stock valued at \$54.2 billion, options on Pfizer common stock valued at \$1.1 billion, Pfizer convertible perpetual preferred stock valued at \$.5 billion, and vested share awards valued at \$.1 billion, as well as transaction costs of \$90 million.

The fair value of Pfizer common stock was derived using an average market price per share of Pfizer common stock of \$29.81, which was based on Pfizer's average stock price for the period two days before through two days after the terms of the acquisition were agreed to and announced on July 15, 2002.

Under the terms of the merger agreement, each outstanding share of Pharmacia common stock was exchanged for 1.4 shares of Pfizer common stock in a tax-free transaction. Each share of Pharmacia Series C convertible perpetual preferred stock was exchanged for a newly created class of Pfizer Series A convertible perpetual preferred stock with rights substantially similar to the rights of the Pharmacia Series C convertible perpetual preferred stock.

The acquisition has been accounted for as a purchase business combination. Under the purchase method of accounting, the assets acquired and liabilities assumed from Pharmacia are recorded at the date of acquisition, at their respective fair values. Financial statements and reported results of operations of Pfizer issued after completion of the acquisition will reflect these values, but will not be restated retroactively to reflect the historical financial position or results of operations of Pharmacia.

This transaction resulted in the issuance of approximately 1.8 billion shares of Pfizer common stock, six thousand shares of Pfizer Series A convertible perpetual preferred stock, which are convertible into 15.5 million shares of Pfizer common stock, and 180 million Pfizer stock options. We recorded approximately \$21.7 billion of goodwill, \$25.1 billion of purchased intangibles with finite lives (which includes \$24.9 billion of developed technology rights) and \$9.4 billion of purchased intangibles with indefinite lives (which includes \$8.9 billion of brands) in conjunction with the acquisition based on preliminary estimates of an independent valuation specialist.

Developed technology rights represent the value associated with developed technology to which Pfizer has all associated rights. These rights can include the right to develop, use, market, sell and/or offer for sale the technical processes, intellectual property and institutional understanding (including the way in which compounds react in body, an understanding of the mechanisms of action which allows the compound to work and the knowledge related to the associated clinical and marketing studies performed for these compounds) that were acquired from Pharmacia with respect to products, compounds and/or processes that have been completed. The valuation of these developed technology rights is derived from multiple cash flow streams, some of which are more certain than others. For example, the valuation of Pharmacia's second-generation COX-2 inhibitor, *valdecoxib*, includes the cash flows associated with the sale of Bextra, the product line approved by regulators for the treatment of osteo and rheumatoid arthritis, as well as the value associated with using the developed technology (*valdecoxib*) in future IPR&D projects. In this situation, the cash flows of the approved indications are more likely to be achieved than the potential cash flows associated with the R&D projects for the currently unapproved indications. The unequal probability of realizing these cash flow streams reflects the uncertainty associated with the future benefits of individual R&D projects, even those that leverage the benefits of developed technology. Of the value allocated to developed technology rights, approximately 95% is derived from regulatory-approved uses and indications.

Brands with indefinite-life treatment represent the value associated with tradenames, as the products themselves no longer receive patent protection.

The fair value of all of these intangible assets is determined using an income approach on a project-by-project basis. This method starts with a forecast of all of the expected future net cash flows associated with the developed technology (both approved and unapproved uses), the brands and the other intangible assets. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams.

The forecast of future cash flows requires the following assumptions to be made:

- Revenue that is reasonably likely to result from the approved and unapproved uses, if they are successful, including the estimated number of units to be sold, estimated selling prices, estimated market penetration and estimated market share and year-over-year growth rates over the product life cycles.
- Cost of sales related to the potential products using historical data, industry data or other sources of market data.
- Sales and marketing expense using historical data, industry data or other sources of market data.
- General and administrative expenses.
- Research and development (R&D) expenses.
- The estimated life of the potential product.

The valuations are based on the information that is currently available and the expectations and assumptions that have been deemed reasonable by our management. No assurance can be given, however, that the underlying assumptions or events associated with such assets will occur as projected. For these reasons, among others, the actual results may vary from the projected results.

At least annually we will evaluate all of these intangible assets for impairment. For developed technology rights, an element of the impairment review process will include an evaluation of the status of the various R&D programs that were used in the fair valuation process. Given the general uncertainty of success that is associated with R&D projects in the pharmaceutical industry, the realization of these cash flow streams (those associated with unapproved indications) is not assured.

In addition, we recorded a charge of \$5.0 billion in the first nine months of 2003 for purchased in-process research and development at the time of acquisition because technological feasibility had not been established and no future alternative uses existed. In connection with the acquisition, management has reviewed the operations of the combined company and has begun to implement several plans to restructure operations-see the discussion above on "Merger-Related Costs".

As a result of the acquisition of Pharmacia, regulatory authorities required us to divest several products and a product candidate. In April 2003, we sold Cortaid, an anti-itch cream, for \$35.8 million in cash. Also in April 2003, we sold the product candidate for overactive bladder, darifenacin, for \$225 million. We received \$50 million in cash upon closing and will receive the remaining \$175 million when darifenacin receives regulatory approvals.

## OUTLOOK

In 2003, we continue to anticipate total revenues of \$45 billion and R&D expenditures of about \$7 billion. In 2004, targeted revenue remains \$54 billion. As is customary, we are currently refining the details of our 2004 operating plan. We will provide investors with a more comprehensive overview of 2004 early next year. Estimated adjusted income and GAAP net income, and items reconciling the two, are as follows for the fourth quarter of 2003 and full-year 2003:

	Fourth Quarter	Full Year
	2003 Estimate	2003 Estimate
(in billions, except share data which is in millions)	Net Income	Net Income
Adjusted income	\$3.8	\$12.6
In-process R&D	--	5.0
Workdown of inventory write-up to fair value, after tax	.9	2.1
Intangible amortization/fixed asset depreciation, after tax	.5	1.4
Merger-related costs, after tax	.3	.8
Significant items/change in accounting principle, after tax	.2	(1.9)
GAAP earnings	<u>\$1.9</u>	<u>\$ 5.2</u>

Although we have agreed to explore strategic options for the diagnostics and surgical ophthalmology businesses, we do not predict divestitures of businesses or products in these forecasts.

Cost synergies from the Pharmacia acquisition achieved in the first nine months of 2003 totaled more than \$600 million. Cumulative cost synergies resulting from the acquisition of Pharmacia are expected to be at least \$1 billion in 2003, about \$3 billion in 2004, and about \$4 billion in 2005. Synergies will come from a broad range of sources, including a streamlined organization, reduced operating expenses, and procurement savings. Total merger-related costs incurred over the next three years to achieve these synergies are expected to be in the range of \$4.7 billion to \$5.2 billion, pre-tax.

## RECENTLY ISSUED ACCOUNTING STANDARD

In April 2003, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards (SFAS) No. 149, *Amendment of Statement 133 on Derivative Instruments and Hedging Activities*. SFAS No. 149 amends and clarifies accounting for derivative instruments, including certain derivative instruments embedded in other contracts, and for hedging activities under SFAS No. 133. The provisions of SFAS No. 149 are generally effective for contracts entered into or modified after June 30, 2003 and for hedging relationships designated after June 30, 2003. We do not expect the adoption of SFAS No. 149 to have a material impact on our financial position, results of operations or cash flows.

## CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS

Our disclosure and analysis in this report contain forward-looking information about our company's financial results and estimates, business prospects and products in research that involve substantial risks and uncertainties. From time to time, we also may provide oral or written forward-looking statements in other materials we release to the public. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historic or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "will," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies, such as legal proceedings, and financial results. Among the factors that could cause actual results to differ materially are the following:

- the success of research and development activities and the speed with which regulatory authorizations, pricing approvals, and product launches may be achieved
- competitive developments affecting our current growth products
- the ability to successfully market both new and existing products domestically and internationally
- difficulties or delays in manufacturing

- trade buying patterns
- the ability to meet generic and branded competition after the loss of patent protection for our products
- trends toward managed care and health care cost containment
- possible U.S. legislation or regulatory action affecting, among other things, pharmaceutical pricing and reimbursement, including Medicaid and Medicare and involuntary approval of prescription medicines for over-the-counter use
- legislation or regulations in markets outside the U.S. affecting product pricing, reimbursement or access
- contingencies related to actual or alleged environmental contamination
- legal defense costs, insurance expenses, settlement costs and the risk of an adverse decision or settlement related to product liability, patent protection, government investigations, and other legal proceedings
- the company's ability to protect its patents and other intellectual property both domestically and internationally
- interest rate and foreign currency exchange rate fluctuations
- governmental laws and regulations affecting domestic and foreign operations, including tax obligations
- changes in generally accepted accounting principles
- any changes in business, political and economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas
- growth in costs and expenses
- changes in our product mix
- the impact of acquisitions, divestitures, restructurings, product withdrawals and other unusual items, including our ability to integrate and to obtain the anticipated results and synergies from our acquisition of Pharmacia

We cannot guarantee that any forward-looking statement will be realized, although we believe we have been prudent in our plans and assumptions. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our Forms 10-Q, 8-K and 10-K reports to the Securities and Exchange Commission. Our Form 10-K filing for the 2002 fiscal year listed various important factors that could cause actual results to differ materially from expected and historic results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. Readers can find them in Item 1 of that filing under the heading "Cautionary Factors That May Affect Future Results." We incorporate that section of that Form 10-K in this filing and investors should refer to it. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.

#### Legal Proceedings and Contingencies

We and certain of our subsidiaries are involved in various patent, product liability, consumer, commercial, environmental, and tax litigations and claims; government investigations; and other legal proceedings that arise from time to time in the ordinary course of our business. We do not believe any of them will have a material adverse effect on our financial position. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe we have valid defenses in these matters, we could in the future incur judgments or enter into settlements of claims that could have a material adverse effect on our results of operations in any particular period.

Patent claims include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe that we have valid defenses to these challenges with respect to all our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the drug at issue, which could lead to a significant loss of sales of that drug and could materially affect future results of operations.

#### Item 4. Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information required to be disclosed in our periodic reports filed with the SEC.

In addition, we evaluated our internal control over financial reporting and there have been no changes that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



## PART II - OTHER INFORMATION

### Item 1. Legal Proceedings

Certain legal proceedings in which Pfizer is involved are discussed in Note 20 to the consolidated financial statements in Pfizer's 2002 Annual Report to Shareholders; Part I, Item 3, of Pfizer's Annual Report on Form 10-K for the year ended December 31, 2002; and Part II, Item 1, of Pfizer's Quarterly Reports on Form 10-Q for the quarters ended March 30 and June 29, 2003. The following discussion is limited to recent developments concerning certain of Pfizer's legal proceedings and should be read in conjunction with those earlier Reports. Unless otherwise indicated, all proceedings discussed in those earlier Reports remain outstanding.

#### **Patent Matters**

##### Norvasc

As previously reported, a manufacturer filed an application with the FDA seeking approval to market amlodipine maleate, a different salt form from amlodipine besylate, which is employed in our product, Norvasc. In June 2002, we filed a patent infringement suit against the manufacturer in the U.S. District Court for the District of New Jersey. The manufacturer's motion to dismiss the complaint was granted in December 2002, and we appealed that decision. A hearing on our appeal was held in July 2003, and we are awaiting the decision of the court. In October 2003, the FDA granted final approval to the manufacturer to market amlodipine maleate. We plan to take legal action to challenge the FDA's approval. If both our challenge of the FDA's approval and our appeal of the District Court's decision are unsuccessful, our sales of Norvasc could be subject to competition from the amlodipine maleate product.

##### PDE5 Inhibitors for the Treatment of Male Erectile Dysfunction

In October 2002, we were granted a broad patent, which expires in 2019, covering the use of orally-effective PDE5 inhibitors for the treatment of male erectile dysfunction. At that time, we brought suit in the U.S. District Court for the District of Delaware against the manufacturers of competing PDE5 inhibitors for infringement of this patent. In October 2003, we received notice that the U.S. Patent and Trademark Office has initiated a reexamination of this patent. The defendants in our suits against competing PDE5 inhibitor manufacturers have filed motions to stay those actions pending the completion of the patent reexamination.

The Patent and Trademark Office reexamination of this use patent and our suits against competing PDE5 inhibitor manufacturers do not involve and will have no effect on our basic product patent for Viagra, which expires in 2012.

#### **Product Liability Matters**

##### Rezulin

As of November 10, 2003, suits involving approximately 10,300 alleged users of Rezulin were pending in various federal and state courts, and approximately 8,200 alleged users had asserted claims but had not filed suits. In addition, as of November 10, 2003, we had agreed to extend the statute of limitations for approximately 23,200 individuals who do not have lawsuits on file and who may or may not eventually pursue claims.

As previously reported, the cases pending in federal courts have all been consolidated for pre-trial proceedings in a single multi-district litigation assigned to the U.S. District Court for the Southern District of New York. In September 2002, the court denied the plaintiffs' motion to certify a class of allegedly injured Rezulin users seeking money damages and a subclass of uninjured users seeking medical monitoring and damages for alleged consumer fraud or restitution of amounts they paid for Rezulin. In denying class certification, the court stated that claimants "took Rezulin at different times, for different periods, in different amounts" and that each claimant presents "unique characteristics such as family and medical background, preexisting medical conditions, age, gender, life style, drug or alcohol use, quantity of Rezulin ingested, duration of course of treatment, and whether Rezulin was used alone or in conjunction with other drugs".

A number of the other pending cases also are purported class actions. We are opposing class certification in all of those cases. As previously reported, to date class certification has been granted in only one case, which involves a class consisting of all persons who either used or purchased Rezulin in West Virginia. In September 2003, in an action seeking the refund of amounts paid for Rezulin that was not used by the plaintiffs after the product was withdrawn from the market, a state court in Brazoria, Texas denied certification of a class consisting of all persons who purchased Rezulin in Texas.

We are actively engaged in defending, and will continue to explore the resolution of, these cases and claims.

## Asbestos

As of September 30, 2003: (i) approximately 161,800 claims naming Pfizer and/or Quigley Company, Inc. (which is a subsidiary of Pfizer) and numerous other defendants were pending in various federal and state courts seeking damages for alleged asbestos and other exposures, and (ii) approximately 128,600 claims naming American Optical Corporation (which is a former subsidiary of Warner-Lambert) and numerous other defendants were pending in various federal and state courts seeking damages for alleged asbestos and other exposures.

## Monsanto-Related Matters

As previously reported, Pharmacia Corporation is a defendant in various actions in state and federal court in Alabama relating to polychlorinated biphenyls ("PCBs") that were discharged from a plant site in Anniston, Alabama. The principal actions against Pharmacia are *Abernathy et al. v. Monsanto et al.* and *Tolbert et al. v. Solutia et al.* In August 2003, both of these actions were settled, subject to the execution of releases by the plaintiffs, without the payment of a material amount by Pharmacia or Pfizer.

## Average Wholesale Price Litigation

As previously reported, a number of states and counties have sued Pharmacia, Pfizer and other pharmaceutical manufacturers alleging that they sold certain products at prices lower than the published average wholesale price ("AWP"). The AWP is used to determine reimbursement levels under Medicare Part B and under many private-sector insurance policies and medical plans. Several of the suits also allege that Pharmacia did not report to the states its best price for certain products under the Medicaid program. Each of these suits alleges, among other things, deceptive trade practices and fraud and seeks monetary and other relief, including civil penalties and treble damages.

In addition, Pharmacia, Pfizer and other pharmaceutical manufacturers are defendants in a number of purported class action suits in various federal and state courts brought by individuals, employee welfare plans and self-styled public interest groups that state claims similar to those in the state and county actions. These suits allege, among other things, fraud, unfair competition and unfair trade practices and seek monetary and other relief, including civil penalties and treble damages.

All of these state, county and purported class action suits were transferred to the U.S. District Court for the District of Massachusetts for consolidated pre-trial proceedings. Certain of the plaintiff states have filed motions to remand their actions to their respective state courts, and several of these actions have been remanded. After the court in the consolidated proceeding in Massachusetts granted in part and denied in part defendants' motions to dismiss the master consolidated complaint in May 2003, the plaintiffs filed an amended master consolidated complaint in June 2003. In August 2003, defendants filed motions to dismiss the amended complaint.

## Neurontin

As previously reported, the U.S. Attorney's office in Boston, Massachusetts has been conducting an investigation into Warner-Lambert's promotion of Neurontin. The investigation originated with a *qui tam* lawsuit filed in the U.S. District Court for the District of Massachusetts by a former Warner-Lambert employee, alleging that Warner-Lambert violated the Federal False Claims Act based on certain sales and marketing practices concerning Neurontin. These allegations are also being investigated by various state attorneys general. We are continuing to cooperate fully with these inquiries and to attempt to resolve these matters through settlement, provided that certain essential terms and conditions can be satisfied. Any such resolution would result in the payment of fines and penalties. These allegations are also the subject of a number of suits, including purported class actions, filed on behalf of private parties in various federal and state courts.

## Tax Matters

The Internal Revenue Service (IRS) has completed and closed its audits of Pfizer Inc's tax returns through 1998 and Warner-Lambert Company through 1995. The IRS is currently conducting audits of Pfizer Inc's tax returns for the years 1999 through 2001 and Warner-Lambert Company for the years 1996 through 1998. With respect to Pharmacia, the IRS is currently conducting audits of Pharmacia Inc.'s tax returns for the years 1998 and 1999, while its tax returns for 1995 through 1997 are open and under appeal. Pharmacia also has responsibility for the currently on-going IRS audit of its former agricultural subsidiary Monsanto's tax returns for the years 1998 and 1999.

We believe that our accrual for tax liabilities is adequate for the relevant periods.

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

- 1) Exhibit 12 - Ratio of Earnings to Fixed Charges and Ratio of Earnings to Fixed Charges and Preferred Stock Dividends
- 2) Exhibit 15 - Accountants' Acknowledgment
- 3) Exhibit 31.1 - Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 4) Exhibit 31.2 - Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 5) Exhibit 32.1 - Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 6) Exhibit 32.2 - Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(b) Reports on Form 8-K

We filed reports on Form 8-K during the third quarter ended September 28, 2003 dated July 25, 2003 and September 4, 2003. On June 30, 2003 we filed a report on Form 8-K/A for pro forma financial information in connection with our acquisition of Pharmacia Corporation.

PFIZER INC. AND SUBSIDIARY COMPANIES

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.

Pfizer Inc.

(Registrant)

Dated: November 12, 2003

/s/ Loretta V. Cangialosi

Loretta V. Cangialosi, Vice President, Controller  
(Principal Accounting Officer and  
Duly Authorized Officer)

PFIZER INC. AND SUBSIDIARY COMPANIES  
RATIO OF EARNINGS TO FIXED CHARGES AND RATIO OF EARNINGS TO FIXED  
CHARGES AND PREFERRED STOCK DIVIDENDS

	Nine Months Ended Sept. 28, 2003	Year Ended December 31,				
(in millions, except ratios)		2002	2001	2000	1999	1998
Determination of earnings:						
Income from continuing operations before provision for taxes on income, minority interests and cumulative effect of change in accounting principles	\$ 2,312	\$ 11,796	\$ 9,984	\$ 5,501	\$ 6,945	\$ 4,397
Less:						
Minority interests	<u>1</u>	<u>6</u>	<u>14</u>	<u>13</u>	<u>5</u>	<u>2</u>
Adjusted income	2,311	11,790	9,970	5,488	6,940	4,395
Fixed charges	<u>273</u>	<u>365</u>	<u>359</u>	<u>478</u>	<u>463</u>	<u>334</u>
Total earnings as defined	<u>\$ 2,584</u>	<u>\$ 12,155</u>	<u>\$ 10,329</u>	<u>\$ 5,966</u>	<u>\$ 7,403</u>	<u>\$ 4,729</u>
Fixed charges:						
Interest expense <sup>(a)</sup>	\$ 185	\$ 251	\$ 266	\$ 381	\$ 364	\$ 251
Preferred stock dividends	<u>2</u>	<u>--</u>	<u>--</u>	<u>--</u>	<u>--</u>	<u>--</u>
Rents <sup>(b)</sup>	<u>86</u>	<u>114</u>	<u>93</u>	<u>97</u>	<u>99</u>	<u>83</u>
Fixed charges	<u>273</u>	<u>365</u>	<u>359</u>	<u>478</u>	<u>463</u>	<u>334</u>
Capitalized interest	<u>17</u>	<u>28</u>	<u>56</u>	<u>46</u>	<u>40</u>	<u>26</u>
Total fixed charges	<u>\$ 290</u>	<u>\$ 393</u>	<u>\$ 415</u>	<u>\$ 524</u>	<u>\$ 503</u>	<u>\$ 360</u>
Ratio of earnings to fixed charges	<u>8.9</u>	<u>30.9</u>	<u>24.9</u>	<u>11.4</u>	<u>14.7</u>	<u>13.1</u>

All financial data for 2003, 2002, 2001 and 2000 reflect our confectionery, shaving and fish-care products businesses as well as the Estrostep, Loestrin and femhrt women's health product lines as discontinued operations. We have not restated periods prior to 2000 for these discontinued operations because the data are not available. After we reorganized our financial systems due to the merger with Warner-Lambert Company, the level of detail necessary to develop financial information for these discontinued operations for periods prior to 2000 was no longer available.

(a) Interest expense includes amortization of debt discount and expenses.

(b) Rents included in the computation consist of one-third of rental expense which we believe to be a conservative estimate of an interest factor in our leases, which are not material.

## ACCOUNTANTS' ACKNOWLEDGMENT

To the Shareholders and Board of Directors of Pfizer Inc.:

We hereby acknowledge our awareness of the incorporation by reference of our report dated November 12, 2003, included within the Quarterly Report on Form 10-Q of Pfizer Inc. for the quarter ended September 28, 2003, in the following Registration Statements:

- Form S-8 dated October 27, 1983 (File No. 2-87473),
- Form S-8 dated March 22, 1990 (File No. 33-34139),
- Form S-8 dated January 24, 1991 (File No. 33-38708),
- Form S-8 dated November 18, 1991 (File No. 33-44053),
- Form S-3 dated May 27, 1993 (File No. 33-49629),
- Form S-8 dated May 27, 1993 (File No. 33-49631),
- Form S-8 dated May 19, 1994 (File No. 33-53713),
- Form S-8 dated October 5, 1994 (File No. 33-55771),
- Form S-3 dated November 14, 1994 (File No. 33-56435),
- Form S-8 dated December 20, 1994 (File No. 33-56979),
- Form S-8 dated March 29, 1996 (File No. 33-02061),
- Form S-8 dated September 25, 1997 (File No. 333-36371),
- Form S-8 dated April 24, 1998 (File No. 333-50899),
- Form S-8 dated April 22, 1999 (File No. 333-76839),
- Form S-8 dated June 19, 2000 (File No. 333-90975),
- Form S-8 dated June 19, 2000 (File No. 333-39606),
- Form S-8 dated June 19, 2000 (File No. 333-39610),
- Form S-3 dated October 20, 2000 (File No. 333-48382),
- Form S-8 dated April 27, 2001 (File No. 333-59660),
- Form S-8 dated April 27, 2001 (File No. 333-59654),
- Form S-3 dated October 30, 2002 (File No. 333-100853),
- Form S-8 dated April 16, 2003 (File No. 333-98105),
- Form S-8 dated April 16, 2003 (File No. 333-104581), and
- Form S-8 dated April 16, 2003 (File No. 333-104582).

Pursuant to Rule 436(c) under the Securities Act of 1933, such report is not considered a part of a registration statement prepared or certified by an accountant or a report prepared or certified by an accountant within the meaning of Sections 7 and 11 of that Act.

KPMG LLP

New York, New York  
November 12, 2003